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The midbrain ventrolateral periaqueductal gray (vlPAG) is a component of the descending pain
modulatory pathway and activation of µ-opioid receptors (MOPr) in this region produces antinoci-
ception in mice. The vlPAG is also a site of modulation of opioid tolerance, a phenomenon that
emerges as a result of chronic opioid use and necessitates increasing the dose of opioid to achieve
desired levels of pain relief. Studies into the mechanism of opioid tolerance have shown that the
vlPAG undergoes adaptations in intracellular signaling following long-term opioid use. However,
the dynamics of intracellular second messenger signaling in the vlPAG following chronic opioid use
have yet to be fully examined. In this thesis, I use the MOPr agonist, morphine to characterize MOPr
downstream protein kinase activation and localization patterns in the vlPAG. I first show that key in-
tracellular kinases, Extracellular Signal-Regulated Kinase 1/2 (ERK 1/2), Protein Kinase-C (PKC),
and Protein Kinase-A (PKA) are significantly increased in activity following morphine tolerance in
both male and female mice. I then examine the behavioral correlates of PKC activity within this
brain region. I show that sustained inhibition of PKC activity only within the vlPAG blocks the
development of morphine antinociceptive tolerance in mice treated with chronic morphine. I also
show that continuous blockade of PKC activity in this brain region enhances morphine antinocicep-
tion in opioid naive mice. Finally, as long-term opioid use is associated with multiple negative side
effects, I explored the role of the receptor GPR171 as a therapeutic target for chronic neuropathic
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and inflammatory pain. I show that the GPR171 agonist, MS15203, reduces chronic neuropathic
and inflammatory pain in male, but not in female mice. Taken together, this thesis identifies key
intracellular signaling alterations within the vlPAG following chronic morphine, identifies the con-
tribution of an individual kinase within this brain region in the development of opioid tolerance, and




The Periaqueductal Grey in Opioid Tolerance and Chronic Pain
Akila Ram
Pain is the body’s natural warning system to indicate one is in an environment highly detrimen-
tal to survival. The body’s response to the sensation of pain is to immediately withdraw from this
environment, ensuring continued survival. However, when pain lasts beyond the window in which
it is useful, it no longer serves as a helpful warning system but instead degrades the quality of life.
Chronic pain leads to patients seeking opioids to alleviate their condition and regain control of their
lives. A severe negative side effect of the use of opioids to treat chronic pain is the development
of tolerance - a condition where, due to prolonged usage of opioids, the body fails to produce the
desired levels of pain relief from the opioid dose. This necessitates increasing the dose of opioid
and puts one at a greater risk of developing further negative side effects such as dependence and
addiction. In the early 1990s we learned that tolerance to opioids, such as the drug morphine, is
created and regulated in the brain. Specifically, it is created by adaptations within neurons in a
midbrain region called the ventrolateral periaqueductal gray (vlPAG). This thesis has three central
objectives - first to delve deeper into the vlPAG to better describe the neuronal adaptations that
follow morphine tolerance, second to examine in greater specificity the contributions of a singular
protein, Protein Kinase-C, in the development of morphine tolerance and third, to evaluate a novel
non-opioid compound as a therapeutic for chronic pain. The studies in this thesis describe the nature
and mechanism of adaptations that occur in vlPAG neurons following morphine tolerance and, in
addition, describe a sex-specific non-opioid therapeutic for chronic pain.
vi
ACKNOWLEDGMENTS
Foremost, I want to thank my advisor, Erin Bobeck for mentoring me through my PhD and for
helping me grow as a scientist and researcher. I would not be where I am today if not for Erin’s
leadership.
My sincere thanks to the graduate and undergraduate researchers of the Bobeck lab for their
support.
Thank you, Samridhi, Laavanya, and Mathangi for being there for me through the good days
and the tough times, and my amazing friends across the country for their relentless support and
optimism.
My parents, Ram and Vasu, and my brother Siva, for bearing with me as I moved across the
world to get a PhD.
My amazing partner, Siddharth, for all the sacrifices he’s made for me and for being a pillar of
support through graduate school.
Last but not the least, this thesis was written as the world is on the horizon of emerging out
from the COVID-19 pandemic. Thank you to all the healthcare workers and researchers who have




ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iii
PUBLIC ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v
ACKNOWLEDGMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vi
LIST OF TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
LIST OF FIGURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . x
ACRONYMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xi
1 INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
2 MORPHINE-INDUCED KINASE ACTIVATION AND LOCALIZATION IN THE PERI-
AQUEDUCTAL GRAY OF MALE AND FEMALE MICE . . . . . . . . . . . . . . . . . . . . . . . 7
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.2.1 Animals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.2.2 Study design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.2.3 Drug treatment: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.2.4 Thermal nociception assays . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.2.5 Immunofluorescence staining and digital image acquisition . . . . . . . . . 10
2.2.6 Image processing and fluorescence quantification . . . . . . . . . . . . . . 11
2.2.7 Statistical analysis: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.3.1 Sex differences in the development of antinociceptive tolerance . . . . . . 13
2.3.2 Chronic morphine activates endosome-lined ERK 1/2 in the vlPAG . . . . 15
2.3.3 Chronic morphine activates Protein Kinase-C in the vlPAG . . . . . . . . . 17
2.3.4 Chronic morphine activates Protein Kinase-A in the vlPAG . . . . . . . . . 17
2.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.4.1 Extracellular Signal-Regulated Kinase 1/2 . . . . . . . . . . . . . . . . . . 22
2.4.2 Protein Kinase-C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.4.3 Protein Kinase-A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.4.4 Sex-Differences in Morphine Tolerance . . . . . . . . . . . . . . . . . . . 25
3 INHIBITION OF PROTEIN KINASE-C WITHIN THE VENTROLATERAL PERIAQUE-
DUCTAL GRAY COUNTERACTS THE DEVELOPMENT OF MORPHINE ANTINOCICEP-
TIVE TOLERANCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.2.1 Animals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
viii
3.2.2 Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.2.3 Stereotaxic surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.2.4 Intra-vlPAG microinjection . . . . . . . . . . . . . . . . . . . . . . . . . . 32
3.2.5 Behavior testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
3.2.6 Immunofluorescence staining and confocal microscopy . . . . . . . . . . . 32
3.2.7 Quantification of fluorescence intensity and signal overlap . . . . . . . . . 33
3.2.8 Statistical Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
3.3.1 Activated Protein Kinase-C is co-localized with the µ-opioid receptor in the
ventrolateral PAG following morphine tolerance . . . . . . . . . . . . . . 35
3.3.2 Acute Protein Kinase-C inhibition does not affect morphine antinociception 37
3.3.3 Inhibition of Protein Kinase-C within the vlPAG prevents the development
of morphine antinociceptive tolerance . . . . . . . . . . . . . . . . . . . . 37
3.3.4 Non-vlPAG inhibition of Protein Kinase-C does not prevent the develop-
ment of morphine antinociceptive tolerance . . . . . . . . . . . . . . . . . 40
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
4 GPR171 ALLEVIATES CHRONIC NEUROPATHIC AND INFLAMMATORY PAIN IN
MALE, BUT NOT FEMALE MICE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
4.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
4.2.1 Animals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
4.2.2 CFA-induced inflammatory pain . . . . . . . . . . . . . . . . . . . . . . . 47
4.2.3 Assessment of inflammatory pain in mice . . . . . . . . . . . . . . . . . . 47
4.2.4 Chemotherapy-induced peripheral neuropathy . . . . . . . . . . . . . . . . 48
4.2.5 Assessment of mechanical allodynia in mice . . . . . . . . . . . . . . . . 48
4.2.6 Drug treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
4.2.7 Immunofluorescence staining and microscopy . . . . . . . . . . . . . . . . 49
4.2.8 Quantification of immunofluorescence . . . . . . . . . . . . . . . . . . . . 50
4.2.9 Quantitative RT-PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
4.2.10 Statistical Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
4.3.1 GPR171 agonist does not reduce chronic inflammatory pain in female mice 51
4.3.2 GPR171 agonist reduces chronic inflammatory pain in male mice . . . . . 53
4.3.3 GPR171 agonist does not alleviate chronic neuropathic pain in female mice 55
4.3.4 GPR171 agonist reduces chronic neuropathic pain in male mice . . . . . . 57
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
5 GENERAL DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70




2.1 Differential kinase expression patterns after acute and chronic morphine in male and
female mice. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.2 Equipment settings for 20x and 63x objectives . . . . . . . . . . . . . . . . . . . . 28
2.3 Laser settings for fluorophore detection . . . . . . . . . . . . . . . . . . . . . . . 28
3.1 ED50 values for morphine on the hot plate and tail flick test after intra-vlPAG mi-
croinjection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
3.2 ED50 values for morphine on the hot plate and tail flick test after non-targeted intra-
vlPAG microinjection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41




2.1 Chronic morphine produces differences in antinociceptive tolerance in male and
female mice. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.2 Chronic morphine elevated levels of pERK 1/2 in the vlPAG which colocalizes with
the endosome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.3 Chronic morphine increased levels of pPKC in the vlPAG. . . . . . . . . . . . . . 18
2.4 Chronic morphine elevated global levels of pPKA substrate in the vlPAG but re-
sulted in fewer nuclear translocations of the substrate. . . . . . . . . . . . . . . . . 19
2.5 Chronic morphine alters intracellular signaling pathways within the vlPAG. . . . . 21
3.1 Activated Protein Kinase-C is co-localized with the µ-opioid receptor in the ventro-
lateral PAG following morphine tolerance. . . . . . . . . . . . . . . . . . . . . . . 36
3.2 Acute Protein Kinase-C inhibition does not affect morphine antinociception. . . . . 38
3.3 Inhibition of Protein Kinase-C within the vlPAG prevents the development of mor-
phine antinociceptive tolerance. . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.4 Non-vlPAG inhibition of Protein Kinase-C does not prevent the development of
morphine antinociceptive tolerance. . . . . . . . . . . . . . . . . . . . . . . . . . 40
4.1 GPR171 agonist does not reduce chronic inflammatory pain in female mice. . . . . 52
4.2 GPR171 agonist reduces chronic inflammatory pain in male mice. . . . . . . . . . 54
4.3 GPR171 agonist does not reduce chronic neuropathic pain in female mice. . . . . . 56
4.4 GPR171 agonist reduces chronic neuropathic pain in male mice. . . . . . . . . . . 58
4.5 Estrus stage does not impact baseline thresholds of female mice. . . . . . . . . . . 63




AKIP-1 A-Kinase Interacting Protein-1
ANOVA Analysis of Variance
AU Arbitrary Units
β-Arr β-Arrestin
BSA Bovine Serum Albumin
cAMP cyclic Adenosine Monophosphate
cDNA complementary Deoxyribonucleic Aicd
CFA Complete Freund’s Adjuvant
CI Confidence Interval
CIPN Chemotherapy-Induced Peripheral Neuropathy
CTCF Corrected Total Cell Fluorescence
DAMGO [D-Ala2, N-MePhe4, Gly-ol]-enkephalin
ERK 1/2 Extracellular Signal-Regulated Kinase 1/2
GABA γ-amino butyric acid
GRK G-protein Receptor Kinase
IHC Immuno-Histo-Chemistry
MOPr µ-Opioid Receptor




qRT-PCR quantitative Real-Time Polymerase Chain Reaction
RNA Ribonucleic Acid
RVM Rostral Ventromedial Medulla
SEM Standard Error of Mean
vlPAG ventrolateral Periaqueductal Gray
CHAPTER 1
INTRODUCTION
The ongoing opioid crisis in the United States has spurred efforts to develop safer analgesics
and to better understand the neural mechanisms of opioid tolerance and addiction. It is imperative to
recognize the intracellular and circuit level changes that occur during the transition from analgesia
to tolerance, so they may be addressed before the symptoms of dependence develop.
The ventrolateral periaqueductal gray
A core component of the central mechanism of descending pain modulation pathway is the
ventrolateral periaqueductal gray (vlPAG). While the PAG in its entirety is subdivided into regions
essential for behavior ranging from arousal to defensive evasion, the ventrolateral region has been
specifically implicated in its role to produce antinociception [1, 2]. The neurons of the vlPAG that
project to the rostral ventromedial medulla mediate this behavioral effect. These neurons are pri-
marily inhibitory GABA-ergic neurons, along with a small fraction of excitatory glutamatergic and
dopaminergic D2 neurons [3, 4]. Endogenous opioid peptides such as enkephalins have been shown
to act on the vlPAG neurons, producing pain relief in situations such as stress-induced analgesia [5].
The presence of opioid receptors, including the µ-opioid receptor, facilitates the antinociceptive
function of the vlPAG.This particular brain region is special interest in the study of opioid-induced
pain relief as intracellular adaptations within the vlPAG neurons facilitate the development of opioid
tolerance [6].
Opioid tolerance
Opioids, such as morphine and fentanyl, act as powerful pain-relieving agents in the short
term. However, continued usage of these drugs produces adaptations within the descending pain
modulatory system, decreasing the ability of the drug to produce pain relief. This necessitates
increasing the dosage of the opioid to achieve the required level of pain relief so the patient may not
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experience a decline in quality of life. However, as opioids also act at multiple targets in the body,
including the gastrointestinal system and the reward pathway in the brain, increasing the dose of
opioids creates imbalances of these physiological functions [7]. To develop better targeted therapies
that produce lasting pain relief without disrupting other physiological systems, the changes that
are produced in the vlPAG neurons as a result of chronic opioid exposure must first be elucidated.
There is substantial evidence that the intracellular signaling pathway at the µ-opioid receptor is
altered following exposure to chronic morphine.
Intracellular signaling at the µ-opioid receptor
The µ-opioid receptor (MOPr) is a member of the Class A family of G-protein coupled recep-
tors, wherein its primary characteristic is its multipass transmembrane structure with seven subunits
[8]. The intracellular C-terminal tail of the receptor is coupled with a heterotrimeric G-protein,
including an inhibitory G-protein, the Gβ and Gγ subunits. Within the vlPAG, MOPr is primarily
expressed in GABA-ergic neurons that project to the medulla. Activation of the MOPr via agonists
such as morphine, inhibits the release of GABA from these projections neurons, thereby disinhibit-
ing the neurons of the medulla and resulting in antinociception at the spinal cord [9].
The development of antinociceptive tolerance to opioids has been linked to MOPr-dependent changes
within the vlPAG. At the circuitry level, opioid tolerance is the term given to the physiological state
when activation of the MOPr does not produce adequate disinhibition of the medullary neurons.
This occurs when the activation of MOPr in the vlPAG projection neurons does not sufficiently
inhibit the release of GABA, owing to a dysregulated communication from the receptor to the neu-
rotransmitter vesicle [10]. While the precise nature of these adaptations is under intense scrutiny,
there is considerable evidence to suggest that following persistent activation of the MOPr, there is
an agonist-dependent upregulation of intracellular signaling, such as greater permeability of potas-
sium channels and increased cyclic AMP signaling [11]. In addition to these changes, positive or
negative modulation of protein kinase activity has been hypothesized to be a medium through which
the receptor signaling is dysregulated after opioid tolerance.
The MOPr signals via the G-protein pathway following activation by its agonists. The Gα subunit
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initiates a signaling cascade which begins with the inhibition of enzymatic activity of Adenylyl Cy-
clase (AC). This leads to the inhibition of the kinase Protein Kinase-A. In the interim, the MOPr is
phosphorylated by a kinase such as Protein Kinase-C (PKC) or G-protein Receptor Kinase (GRK)
to terminate further G-protein dependent signaling and desensitize the receptor. This process results
in the recruitment of a scaffolding protein, β-Arrestin, to recruit the cellular endocytosis machin-
ery to internalize the receptor [12]. There is considerable evidence that following persistent MOPr
activation by morphine, there is a shift in the signaling system from a G-protein dependent to a pre-
dominantly β-Arrestin (β-Arr) dependent pathway [13, 14]. A characteristic of a β-Arr-dependent
pathway is the activation of Extracellular Signal-Regulated Kinase (ERK 1/2). Following the as-
sembly of the endocytosis machinery within a clathrin-coated pit, the C-terminal tail of the MOPr
protrudes outside the endocytic vesicle and is associated with β-Arr [15]. This system enables
persistent signaling of the MOPr via β-Arr long after the receptor is no longer on the surface.
Extracellular Signal-Regulated Kinase
ERK 1/2 is a kinase that is essential regulator for neurodevelopment such as memory consolida-
tion, synaptic regulation, and for initiating further signaling cascades [16, 17]. Following activation
of the MOPr by an agonist, ERK 1/2 activation depends on the biased nature of the agonist. Certain
agonists such as fentanyl, produce rapid antinociception and are efficient at recruiting β-Arr to the
receptor. ERK 1/2 can thus be activated acutely by fentanyl. On the other hand, morphine is a weak
recruiter of β-Arr and does not produce ERK 1/2 activation at an acute timepoint [18]. Interest-
ingly, there is recent evidence to show that following chronic morphine treatment, there is a shift
in MOPr signaling from a G-protein dependent to a β-arr dependent pathway [19]. If this were the
case, chronic morphine treatment would produce antinociceptive tolerance when measured at the
behavioral level and also ERK 1/2 activation when measured at the cellular level in the vlPAG.
Protein Kinase-A
PKA is activated when the repressor subunits of the enzyme bind to cAMP and dissociate
from the holoenzyme, thus freeing the catalytic subunit [20]. PKA has been reported to contribute
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to the dampening of GABA inhibition seen in vlPAG neurons following morphine tolerance [10].
Following exposure to chronic morphine, it has been reported that AC undergoes a superactivation
event caused by a switching of the Gα protein from an inhibitory to an excitatory facilitator [21].
While this result has been previously shown in in-vitro culture and ex-vivo slice preparations, this
result has not yet been shown in native tissue from the vlPAG.
Protein Kinase-C
PKC is a downstream kinase activated by the Gβ and Gγ subunits of the MOPr following ac-
tivation by an agonist [22]. Conventional isoforms of PKC have been reported to phosphorylate the
MOPr after activation by morphine, but not fentanyl [23]. This effect is an example of the G-protein
bias of the morphine at the MOPr. Further, dominant-negative PKC and phosphorylation-deficient
MOPr have been shown to be insensitive to the acute effects of morphine in that the receptor signal-
ing was not terminated and PKC was unable to phosphorylate the receptor [24, 25]. However, the
nature of PKC activation, particularly within the vlPAG, following chronic morphine has remained
unexplored.
The multiple facets of chronic pain
Chronic pain is a severe painful sensation that persists long after the initial injury or trauma
has healed. It is a growing public health concern in the united states and contributes to a decreased
quality of life for the patient in addition to lost time and wages in the economy due to the patients’ ill
health. The current opioid epidemic in the united states, which has been the center of multiple legal
battles and humanitarian crises has largely been brought about by the overprescription of opioids
for chronic pain [26]. The crux of the crisis stems from the fact that while opioids are remarkable
at alleviating pain at the short-term, extended use of opioids for months without a plan to taper
off the usage results in disastrous consequences for the patient [27]. In patients with chronic pain,
alternative therapies are needed to address the source of pain in addition to using supplemental
opioids to manage breakthrough pain. Further, while we have coined the umbrella term, chronic
pain, the pathophysiology of this condition differs upon the source of pain.
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In addition to the highly debilitatory nature of chronic pain, there is further reporting that females
are disproportionally affected by chronic pain. This includes higher incidences of reporting of
migraines and fibromyalgia [28, 29]. Further, females are very likely to be prescribed opioids for
the treatment of chronic pain and develop rapid dependence and addiction these drugs [30]. This
is an increasing problem in the study of pain particularly as a majority of historical research into
the central and peripheral mechanisms regulating pain and antinociception were performed in male
animals [31].
Non-opioid treatment of chronic pain
Armed with our new knowledge of the opioid receptor structure and function and with the help
of computations tools to identify and predict functions of recently discovered receptor systems, the
field can make vast progress into developing pain therapeutics that are not derived from opioid nar-
cotics [32]. These new classes of drugs can be developed to target the µ, κ, or δ opioid receptors
or a heteromer thereof, in a way that minimizes its interaction with the reward circuit [33, 34].
Alternatively, the drug can target any of several non-opioid physiological targets that participate in
antinociception, thereby avoiding interactions with opioid receptors altogether [35, 36].
One such target for the non-opioid treatment of chronic pain is the receptor, GPR171. A recently
deorphanized neuropeptide receptor, GPR171 was initially characterized for its role in the hypotha-
lamus to promote feeding upon activation [37, 38]. Along with the observation that its mRNA is
widely expressed in the mouse brain, closer investigation showed that it is present in the vlPAG on
the same neurons that express the MOPr [39, 40]. An exploratory study in the Bobeck lab showed
that the systemic administration of the GPR171 agonist, MS15203, enhanced morphine antinoci-
ception on acute thermal pain tests. Further preliminary investigation by the laboratory into the
dynamics of GPR171 expression in other pain modalities indicated that chronic neuropathic pain
decreased protein levels of this receptor within the vlPAG. Capitalizing on this pain-dependent mod-
ulation of GPR171 levels, we explored the role of this receptor in modulating hypersensitivity and
allodynia in chronic pain modalities in both males and females.
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In the first study, intracellular kinase activation and localization patterns within the vlPAG
were evaluated in male and female mice. The activity of G-protein and β-Arr-dependent second
messenger kinases – ERK 1/2, PKC, and PKA – is elevated within the vlPAG following morphine
tolerance. These kinases also displayed treatment-dependent localization patterns within the vlPAG
that inform the specific adaptations created in vlPAG neurons following morphine tolerance.
In the second study, the contribution of Protein Kinase-C (PKC) activity in the development
of morphine tolerance was examined. PKC association with the MOPr was quantified within the
vlPAG following multiple paradigms of morphine treatment. It is noted that in addition to elevated
pPKC levels in the vlPAG, the activated PKC co-localizes with the MOPr in the vlPAG extensively
after morphine tolerance. Intra-PAG administration of a PKC inhibitor compound, Gö-7874, pre-
vented the development of antinociceptive tolerance towards morphine. Further, inhibition of PKC
activity enhanced the antinociceptive effect of morphine in opioid-naı̈ve mice.
In the third study, the therapeutic potential of the receptor GPR171 was evaluated. A synthetic
agonist of the receptor, compound MS15203, was injected systemically over 5 consecutive days in
male and female mouse models of chronic neuropathic or inflammatory pain. When administered
in male mice experiencing either modality of chronic pain, MS15203 reduced both neuropathic and
inflammatory pain. However, it was found that females undergoing chronic pain did not experience
a reduction in thermal or mechanical hypersensitivity in response to the GPR171 agonist compound.
This study reports a sexual dimorphism in analgesic properties of GPR171.
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CHAPTER 2
MORPHINE-INDUCED KINASE ACTIVATION AND LOCALIZATION IN THE
PERIAQUEDUCTAL GRAY OF MALE AND FEMALE MICE
2.1 Introduction
Opioids, such as morphine, while being highly effective in the treatment of acute pain, have
adverse consequences if consumed long-term. One such consequence of chronic morphine use is
the development of antinociceptive tolerance where a particular dose ceases to relieve pain over
time, thus leading to dose escalation to achieve desired levels of pain relief. In-vitro and in-vivo
studies have indicated that the ventrolateral periaqueductal gray (vlPAG) of the midbrain regulates
the development of opioid antinociceptive tolerance [10, 41, 42, 43]. Neurons in the vlPAG project
to the rostral ventromedial medulla (RVM), which then synapse onto the dorsal horn of the spinal
cord. Activation of the vlPAG by pharmacological or electrophysiological methods disinhibits the
RVM, which subsequently blocks incoming pain signals received by the spinal cord from periph-
eral nociceptors [1, 4, 44]. Upon repeated exposure to opioids, the vlPAG has decreased ability
to produce antinociception and disinhibit the neurons of the RVM [42]. While the behavioral and
electrophysiological outcomes of opioid tolerance have been well established, there is not a clear
consensus on the intracellular adaptations within the vlPAG.
Molecular studies have evaluated µ-opioid receptor-induced G protein and β-arrestin intracel-
lular signaling pathways and have revealed that chronic morphine induces distinct signaling patterns
compared to other opioids [45, 46]. These signaling changes have been implicated in the develop-
ment of opioid tolerance [47, 48]. Furthermore, vlPAG inhibition of G protein-activated enzymes,
such as adenylyl cyclase (AC), c-Jun N-terminal kinase, and protein kinase-C (PKC) leads to a
reduction in the development of morphine tolerance [10, 48? ]. Conversely, inhibition of the β-
arrestin-dependent proteins, ERK 1/2 and GRK, leads to greater tolerance or no change in tolerance
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to morphine [14? ] respectively. However, these studies have predominantly been conducted in
male rodents despite known sex differences in opioid-induced antinociception and tolerance. Typ-
ically, these sex differences manifest as reduced antinociception in females when comparing the
same dose of opioids in males, which has been linked to neuroanatomical differences within the
descending pain pathway. These include a greater density of µ-opioid receptors (MOPr) within
the vlPAG and more opioid sensitive projection neurons from vlPAG to RVM in males [49, 50].
However, intracellular protein-specific alterations in the vlPAG of females have not been studied in
detail and the community lacks a clear comparison of paradigm-specific sex differences in vlPAG
intracellular signaling.
The goal of the current study is to bridge the gap in knowledge regarding the intracellular kinase
signaling profile within the vlPAG following acute and chronic morphine treatment in both male and
female mice. Overall, we find similar patterns of morphine-induced activation of several key kinases
in both sexes, but the magnitude of expression is typically greater in males. Furthermore, we find
that kinases downstream of β-arrestin are colocalized to endosomes only after chronic morphine,
whereas G-protein associated kinases are localized to the nucleus.
2.2 Materials and Methods
2.2.1 Animals
Adult male and female C57BL/6CS mice (Charles River Laboratories, CA), 6-8 weeks old and
weighing 18-26 g at the start of the study were used in behavioral and immunofluorescence exper-
iments. Food and water were available ad libitum, except during testing. Mice were housed (four
to five per cage) in a humidity and temperature-controlled room with a 12-hour light/dark cycle (off
at 1900). All procedures were performed during the light cycle and in accordance with the Guide
for the Care and Use of Laboratory Animals adopted by the National Institutes of Health. The ani-




This study was not pre-registered. Mice were assigned to treatment groups by block random-
ization, where equal numbers of morphine or saline-treated mice were present. Enumeration of
the nuclear punctae in the pPKA analysis was manually performed by experimenters blinded to the
drug treatments. The experimenter was not blinded to the drug treatments during behavior testing,
automated image analysis, or statistical analysis. No calculations were performed to predetermine
sample size. The study was designed to be exploratory. No exclusion criteria were pre-determined
and no animals were excluded in the experiments performed.
2.2.3 Drug treatment:
Subjects were administered morphine sulfate (West-Ward Pharmaceuticals) dissolved in 0.9%
saline (10 mg/kg in a volume of 10 ml/kg i.p.). For acute morphine treatment, the animals were
administered a single dose of morphine 30 minutes before brain collection. For chronic morphine
treatment, the animals were administered morphine twice daily, for a total of 9 doses. This partic-
ular dose was selected since it is the half-maximal antinociceptive dose (ED50) that also leads to
behavioral tolerance in various strains of male C57BL/6 mice [51, 52, 53]. The subjects’ brains
were collected 30 minutes following the final dose of morphine or saline. This time point has been
previously shown to correspond with peak MAP kinase (eg. ERK 1/2) activation [54] and morphine
antinociception [40].
2.2.4 Thermal nociception assays
Male and female mice were habituated to room temperature apparatus and were handled daily
for 3 days prior to the study. Nociception was assessed using the hot plate (Harvard Apparatus,
Holliston, MA) and warm-water tail flick (Thermo Scientific, Waltham, MA) assays. For the hot
plate assay, mice were placed on a heated surface with the temperature adjusted to 52. Time to the
first sign of nociception, such as paw licking or jump response, on the hot plate was recorded. The
cut-off period for this assay was 60 seconds to minimize tissue damage. For the tail flick assay,
mice were gently restrained and the distal third of their tails were immersed in a water bath set to
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50. The latency in tail withdrawal was recorded and a cut-off period of 20 seconds was maintained
to prevent tissue damage.
Male and female mice were administered morphine (10 mg/kg i.p.) or 0.9% saline (10 ml/kg
i.p.) twice daily for a total of 9 injections. All animals were tested on the hot plate and tail flick
assays prior to drug administration to assess baseline scores. The post-drug testing took place
30 min following drug administration on days 1, 3, and 5; where day 1 is the first day of drug
treatment. Morphine antinociceptive tolerance was assessed by a return to baseline thresholds as
previously established [53, 55]. Following the behavioral study, the mice were classified as chronic
morphine- or saline-treated animals and their brains were isolated for immunofluorescence analysis.
A subset of mice in each treatment group were injected with the drug treatment protocol without
the behavioral testing mentioned above.
2.2.5 Immunofluorescence staining and digital image acquisition
Animals were deeply anesthetized using isofluorane and transcardially perfused with 4% para-
formaldehyde (PFA). Isofluorane was selected as the anesthetic as the circulatory system of the
mouse must be functional for successful transcardial perfusion. Their brains were post-fixed in 4%
PFA for 1 hour following which they were stored in 1x PBS until further processing. Sectioning was
performed on a vibratome (Leica Biosystems, Germany) and 50 µm sections containing the vlPAG
were selected for immunofluorescence analysis. The sections were first incubated in sodium boro-
hydride (1% in PBS) to expose the epitopes. Subsequently, they were permeabilized with Triton-X
100 (Sigma-Aldrich, St. Louis, MO), blocked with normal goat serum (5% in PBS), and incubated
overnight in primary antibodies in their appropriate buffer [1% BSA (Sigma) and 3% Triton X-100
(Sigma) in PBS]. The following day, the slices were washed in PBS and incubated for 2 hours in
diluted secondary antibodies in 1% BSA in PBS. The antibodies were sourced from Cell Signal-
ing Technology (Rabbit anti-pERK 1/2 Cat. 4370S 1:200; Rabbit anti-pPKC Cat. 38938S 1:400;
Rabbit anti-pPKA substrate Cat. 9621S 1:200), Abcam (Goat anti-Eea1 Cat. 208942 1:200), Life
Technologies (Goat anti-Rabbit A594 Cat. A11037 1:1000; Donkey anti-Goat A488 Cat. A11055
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1:1000) and Jackson ImmunoResearch (Donkey anti-Rabbit A594 Cat. 711-586-152 1:1000 ). Fol-
lowing a second incubation with the fluorophore-conjugated antibody and subsequent PBS washes,
the slices were briefly (5 mins) incubated in DAPI, washed with PBS and mounted with an anti-fade
(ProLong Diamond Anti-Fade, Life Technologies) on a glass slide. Confocal images of coronal
sections comprising of the rostrocaudal axis of the vlPAG as, defined by the mouse brain atlas [56],
were acquired on a Zeiss LSM 710 confocal microscope (Carl Zeiss Microscopy, Germany) at Utah
State University’s microscopy core facility. Microscope hardware information and laser settings for
each fluorophore are detailed in Supplementary Note 1.
2.2.6 Image processing and fluorescence quantification
Fluorescence intensities of individual kinases were calculated from unedited images while cor-
recting for local background fluorescence. Briefly, for each image of the vlPAG hemisphere that
was analyzed, 10 regions corresponding to either pERK 1/2, Eea1, pPKC or pPKA substrate were
selected that encompass the entire cell body. Three regions corresponding to local background were
also selected for each image. This process was performed for the left and right vlPAG hemispheres
and repeated across three coronal sections per subject. On average, 20-30 images per condition
were analyzed depending on the kinase, treatment group, sex, and type of analysis performed. Each
IHC image containing one hemisphere of the vlPAG was analyzed as an independent measurement
to account for the structural and functional heterogeneity of the PAG columns [57, 58, 59] in ad-
dition to controlling for the laterality of antinociception in the PAG [60, 61]. We broadly assessed
kinase activation in the vlPAG without filtering cell-type specificity, as was performed previously
[62, 63]. Following automated image thresholding, fluorescence intensities and relevant parameters
were measured with ImageJ (NIH). The corrected total cell fluorescence (CTCF) was calculated for
each cell from the integrated density measurement using the formula: CTCF = Integrated Density
– (Area of selection x background mean fluorescence). The fluorescence intensities were measured
in Arbitrary Units (AU).
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For statistical analyses, average CTCF values of each image in a treatment group were nor-
malized to the average of the saline control group of the specific sex using the formula: Y = [(Y-
K)/K]*100, where Y is the individual data point and K is the overall average of the saline group
for the particular sex and kinase. As there were differences in the saline groups between males and
females, we performed this normalization to better compare morphine-induced kinase activity. Co-
localization of pERK 1/2 and Eea1, imaged using red and green fluorescent channels respectively,
was represented as the Pearson’s correlation coefficient and was calculated using the JACoP plugin
in ImageJ. This was done in order to automate the analysis in an unbiased manner. The plugin mea-
sures overlap between the red and green fluorescent channels with the Pearson’s coefficient (r) being
the output. A coefficient of 1 is indicative of total overlap while a coefficient of 0 implies no overlap.
This method to quantify colocalization of Eea1 with other proteins has been used previously using
immunofluoresence in cells [62]. Representative images from all experiments were processed using
the Iterative Deconvolve 3D macro in ImageJ to enhance signal and remove fluorescent artifacts.
All images were processed through 5 deconvolution cycles.
2.2.7 Statistical analysis:
Morphine antinociceptive tolerance in male and female mice was analyzed using two inde-
pendent two-way ANOVAs. The main effects tested were drug treatment and time. To compare
the acute effects of morphine across sexes, t-tests were performed on the thermal latencies of male
and female mice administered with a single dose of morphine (10 mg/kg). Sex was not included
as a factor in fluorescence quantification or behavior analysis as male and female mice were not
concurrently tested. All fluorescence quantification data are expressed as violin plots showing the
frequency distribution of pooled CTCF values representative of each hemisphere. The median value
along with the 25th and 75th quartiles are indicated within each violin. Normality was measured
using a D’Agonstino & Pearson normality test and variance was measured using Spearman’s test
for heteroscedasticity. The data met the assumptions of normal distribution and homogenous vari-
ance. No statistical test for outliers were performed. Statistical analyses including unpaired t-tests,
one- and two-way ANOVA followed by post-hoc tests, and graphing were performed using Graph-
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Pad Prism 8 (GraphPad, San Diego, CA). Microsoft Excel (Microsoft, Redmond, WA) was used
to calculate CTCF values. The number of subjects and specific statistical analyses used in each
experiment are indicated in the text.
2.3 Results
2.3.1 Sex differences in the development of antinociceptive tolerance
Given the large body of literature pertaining to sex differences in morphine action, we sought
to assess the development of morphine tolerance in male and female mice using a 5-day treatment
paradigm (Fig. 2.1A). We administered systemic morphine (10mg/kg i.p.) twice-daily over the
course of 5 days. In males (n=5/group), morphine produced statistically significant antinociception
on the hot plate (Time [F (3,24) = 13.77, p<0.0001]; Treatment [F (1,8) = 7.583, p<0.5]; Time
x Treatment [F (3, 24) = 7.07, p<0.01]) and tail flick assays (Time F (3,24) = 11.8, p<0.0001];
Treatment [F (1,8) = 26.35, p<0.001]; Time x Treatment [F (3, 24) = 18.08, p<0.0001]) compared
to saline controls as measured by a repeated measures two-way ANOVA. A Bonferroni’s post-hoc
analysis revealed that male mice treated with morphine returned to baseline latency on the hot plate
(Bonferroni p>0.05, morphine group baseline vs Day 5; Fig. 2.1B), which is indicative of the devel-
opment of antinociceptive tolerance to morphine. However, the male mice did not return to baseline
latency by Day 5 on the tail flick assay (Bonferroni p<0.001, morphine group baseline vs Day 5;
Fig. 2.1C). Morphine produced statistically significant antinociception in females (n=5-6/group) on
the hot plate (Time [F (1.8, 16.2) = 12.82, p<0.001]; Treatment [F (1,9) = 31.22, p<0.001]; Time
x Treatment [F (3, 27) = 9.5, p<0.001]) and tail flick assays (Time [F (3,24) = 11.8, p <0.0001];
Treatment [F (1,9) = 36.27, p<0.0001]; Time x Treatment [F (3, 27) = 14.78, p<0.0001]) as mea-
sured by a repeated measures two-way ANOVA. A Bonferroni’s post-hoc analysis revealed that the
morphine-treated females went on to develop tolerance on the hot plate (Bonferroni p>0.05) and
tail flick (Bonferroni p>0.05) tests by Day 5 in comparison to their baseline on Day 0. There was no
sex difference in the acute effect of morphine on either the hot plate (Morphine-Male vs Morphine-
Female, Day 1, unpaired t-test p>.05) or tail flick assays (Morphine-Male vs Morphine-Female,
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Fig. 2.1: Chronic morphine produces differences in antinociceptive tolerance in male and female
mice. (A) An illustrative timeline of the experimental design of the behavioral testing and chronic
morphine or saline treatment paradigm. Male mice (n=5/group) treated with morphine (10 mg/kg)
developed tolerance on the hot plate (B) but not the tail flick (C) assay. Female mice (n=5-6/group)
treated with morphine developed antinociceptive tolerance to morphine by Day 5 of the experiment
on both the hot plate (D) and tail flick (E) assays. Two-way ANOVA with Bonferroni’s post-hoc
test. *p<0.05, **p<0.01, ***p=0.0001 indicate significant differences compared to the treatment
group baseline.
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Day 1, unpaired t-test p>.05). Mice of both sexes that were treated with saline did not display any
change in thermal latency over the course of the study.
2.3.2 Chronic morphine activates endosome-lined ERK 1/2 in the vlPAG
We subsequently set out to assess the activation pattern and localization of ERK 1/2 within
the vlPAG after acute and chronic morphine treatment. We show that morphine treatment produced
statistically significant elevation of pERK 1/2 levels in the vlPAG of both males (n=10 images from
6 mice/group) [F (2, 24) = 21.88, p<0.0001] and females (n=10 images from 5 mice/group) [F (2,
19) = 4.8, p <0.05] as measured by two independent one-way ANOVAs. A Tukey’s post-hoc test
revealed that following acute morphine treatment (10mg/kg), there is a moderate increase in pERK
1/2 activation only in males ( 44% increase vs Saline, Tukey p<0.01; Fig. 2.2A and 2.2B) but not
females (Tukey p>0.05; Fig. 2.2A and 2.2C). The post-hoc analysis further revealed that following
chronic morphine for 5 days, both males (97% increase vs Saline, Tukey p<0.0001; Fig. 2.2B) and
females (51% increase vs Saline, Tukey p <0.01; Fig. 2.2C) show highly elevated levels of pERK
1/2 in the vlPAG compared to the saline controls. See Table 1 for a summary of sex differences
found for all kinases.
To determine whether this ERK 1/2 activity was occurring within endosomes of the vlPAG of
these animals, we performed co-staining of pERK 1/2 with a marker for the early endosome, Early
Endosome Antigen1 (Eea1, Fig. 2.2D). As we did not observe any sex differences in Eea1 signal,
we pooled the data from males and females for further analysis (n=6 images from 5 mice/group).
We note that fluorescence signal from the endosomal marker increases following morphine toler-
ance [F (2, 19) = 7.24, p<0.05] as measured by a one-way ANOVA, but a Tukey’s post-hoc analysis
revealed that the increase is relative only to acute morphine (36% increase vs Acute Morphine,
Tukey p<0.05; Fig. 2.2E).
We next evaluated co-localization of pERK 1/2 and Eea1 signals to calculate an overlap score
indicated by the Pearson’s coefficient (r). We found that there is a statistically significant overlap
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Fig. 2.2: Chronic morphine elevated levels of pERK 1/2 in the vlPAG which colocalizes with the
endosome. (A) 20x Confocal images of the vlPAG stained for pERK 1/2 (red) and counterstained
with DAPI (black). Male (n=5/group) and female (n=5/group) mice were treated with either 1 in-
jection of morphine (10 mg/kg, i.p.) for the acute paradigm or 9 injections of morphine or saline
for the chronic morphine and saline paradigms respectively. Quantification of fluorescence signal
indicates that chronic morphine significantly elevated pERK 1/2 levels in the vlPAG in both males
(n=10 images from 6 mice/group) (B) and females (n=10 images from 5 mice/group) (C), however
acute morphine treatment increased pERK 1/2 only in males. (D) Representative 20x confocal im-
ages of male vlPAG sections co-stained with pERK 1/2 (red) and Eea1 (green) and counterstained
with DAPI (black). (E) Eea1 fluorescence quantification (n=5/group) indicates that the signal is in-
creased in chronic morphine compared to acute morphine. (F) Quantification of pERK 1/2 and Eea1
signal colocalization as measured by the Pearson’s coefficient. Kruskal-Wallis test (ERK-Eea1 co-
localization only), One-way ANOVA & Tukey’s post-hoc test *p<0.05, **p<0.01, ***p=0.0001.
Scale bars = 50 µm.
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between the pERK 1/2 and Eea1 signal as measured by a Kruskal-Wallis test. A Dunn’s post-hoc
analysis revealed that the median difference in signal intensity is higher in chronic morphine animals
(Dunn’s p<0.01 vs acute morphine; Fig. 2.2F) indicating that the enhanced ERK 1/2 signaling in
the vlPAG following morphine tolerance is likely originating at the endosome.
2.3.3 Chronic morphine activates Protein Kinase-C in the vlPAG
We next assessed the activation pattern of pPKC within the vlPAG after acute and chronic
morphine treatment. We show that morphine treatment produced statistically significant elevation
of pPKC levels in the vlPAG of both males (n=10 images from 5 mice/group) [F (2, 21) = 13.34,
p<0.001] and females (n=15 images from 5 mice/group) [F (2, 28) = 8.1, p<0.01] as measured by a
one-way ANOVA. A Tukey’s post-hoc test revealed that pPKC levels remained unchanged in males
(Tukey p>0.05; Fig. 2.3A and 2.3B and females (Tukey p>0.05; Fig. 2.3A and 2.3C) following
acute morphine. However, chronic morphine treatment resulted in a statistically significant increase
in pPKC activation in the vlPAG in males (102% increase vs Saline, Tukey p<0.0001 vs saline Fig.
2.3B) and females (57% increase vs Saline, Tukey p<0.01 vs saline Fig. 2.3A and 2.3C).
2.3.4 Chronic morphine activates Protein Kinase-A in the vlPAG
We next assessed the activation pattern and localization of phosphorylated PKA substrates
within the vlPAG after acute and chronic morphine treatment. We show that morphine treatment
produced statistically significant alterations of PKA substrate phosphorylation in males (n=10 im-
ages from 6 mice/group) [F (2,21) = 10.9, p<0.0001] and females (n=8 images from 5 mice/group)
[F (2,19) = 8.53, p<0.01] as measured by two one-way ANOVAs. A Tukey’s post-hoc analysis re-
vealed that the signal intensity of phosphorylated PKA substrates in males increased following acute
morphine treatment (95% increase vs Saline, Tukey p<0.01 acute morphine vs saline; Fig. 2.4A
and 2.4B) which was similar to the pattern after chronic morphine (115% increase vs Saline, Tukey
p<0.001 chronic morphine vs saline, ns chronic morphine vs acute morphine; Fig 4A and B). On
the other hand, a Tukey’s post-hoc analysis in females revealed that acute morphine treatment did
not elevate PKA substrate phosphorylation (Tukey p>0.05 saline vs acute morphine; Fig. 2.4A and
18
Fig. 2.3: Chronic morphine increased levels of pPKC in the vlPAG. (A) 20x Confocal images of the
vlPAG stained for pPKC (red) and counterstained with DAPI (black). Quantification of fluorescence
signal indicated that chronic morphine significantly elevated pPKC levels in the vlPAG in both males
(B) (n=10 images from 5 mice/group) and females (C) (n=15 images from 5 mice/group). One-way
ANOVA and Tukey’s post-hoc test *p<0.05, **p<0.01, ***p<0.0001. Scale bar = 50 µm.
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Fig. 2.4: Chronic morphine elevated global levels of pPKA substrate in the vlPAG but resulted
in fewer nuclear translocations of the substrate. (A) Representative 20x confocal images of the
vlPAG stained for pPKA substrate (red) and counterstained with DAPI (black). Quantification of
fluorescence signal indicates that chronic morphine significantly elevated pPKC substrate levels
in the vlPAG in both males (B) (n=10 images from 6 mice/group) and females (C) (n=8 images
from 5 mice/group). (D) Representative 63x confocal images of nuclei of vlPAG neurons indicating
nuclear punctae of pPKA substrates. Quantifications of pPKA substrate nuclear punctae in male
(E) and female (F) vlPAG show a reduction in punctae following acute morphine which is further
reduced in males after chronic morphine. One-way ANOVA and Tukey’s post-hoc test *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001. Scale bar = 50 µm (20x) and 10 µm (63x).
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Kinase Sex Acute Morphine Chronic
Morphine
ERK 1/2 Males ↑ ↑↑
Females No change ↑↑
PKC Males No change ↑↑
Females No change ↑↑
PKA Males ↑ ↑
Females No change ↑↑
Table 2.1: Differential kinase expression patterns after acute and chronic morphine in male and
female mice. ↑ indicates significant difference from saline, ↑↑ indicates significant difference from
saline and acute morphine.
2.4C) and chronic morphine treatment resulted in marked elevation of PKA substrate phosphoryla-
tion (74% increase vs Saline, Tukey p<0.01 saline vs chronic morphine, p<0.05 chronic morphine
vs acute morphine; Fig. 2.4A and 2.4C). This elevation of pPKA substrate phosphorylation follow-
ing chronic morphine treatment is indicative of AC superactivation in the vlPAG following persistent
MOPr stimulation.
Over the course of our pPKA substrate analysis, we noticed that there was a remarkable lo-
calization of signal as nuclear punctae. Following manual enumeration of the punctae, we showed
that there was a significant difference in pPKA substrate nuclear punctae numbers between mor-
phine treatments in both males [F (2, 113) = 19.97, p<0.0001] and females [F (2, 191) = 36.66,
p<0.0001] using a one-way ANOVA. A Tukey’s post-hoc analysis revealed that following acute
morphine treatment, there was a significant decrease in the number of nuclear punctae in both males
(Tukey p<0.05 acute morphine vs saline; Fig. 2.4D and 2.4E) and females (Tukey p<0.0001 acute
morphine vs saline; Fig. 2.4D and 2.4F). With continued exposure to morphine, the number of
pPKA substrate nuclear punctae decreased in males (Tukey p<0.001 chronic morphine vs acute
morphine, p<0.0001 chronic morphine vs saline; Fig. 2.4D and 2.4E), but not females (Tukey
p<0.0001 chronic morphine vs saline, p>0.05 chronic morphine vs acute morphine; Fig. 2.4D and
2.4F). While it is not immediately apparent how the nuclear transport of these proteins is impacted
by morphine exposure, this result adds another dimension to the spatiotemporal dynamics of PKA
activity.
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Fig. 2.5: Chronic morphine alters intracellular signaling pathways within the vlPAG. Activated
forms of the kinases ERK 1/2, PKC, and PKA are elevated in the mouse vlPAG after 5 days of
repeated morphine injections. ERK 1/2 is activated as a consequence of β-arrestin recruitment.
PKC is activated via the βγ subunits of the G protein. PKA is activated as a result of adenylyl
cyclase superactivation following prolonged Gαi stimulation.
2.4 Discussion
The current study shows that the protein kinases ERK 1/2, PKC, and PKA are activated in
the vlPAG following repeated morphine. Our conclusions follow an immunofluorescence-based
assessment of kinase activation and localization in the vlPAG, which has not been possible with
other molecular approaches. The elevation in signaling by activated kinases in chronic morphine-
treated animals demonstrates that morphine tolerance can be mapped onto a region of the brain
that modulates antinociception. We found a similar degree of tolerance development in males and
females with the exception of males on the tail flick assay. This correlates with a similar pattern
of kinase activation and localization in the vlPAG following repeated morphine injections despite
differences found after acute morphine. This suggests that the behavioral manifestation of long-
term morphine treatment is regulated by the interaction of multiple signaling systems including, but
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not limited to, the MAP kinase, PKC, and AC-PKA pathways as illustrated in Fig. 2.5.
2.4.1 Extracellular Signal-Regulated Kinase 1/2
G protein-coupled receptors including MOPr engage the β-arrestin pathway in an agonist-
dependent manner to facilitate internalization and recycling of the receptor which is vital to ensure
continued sensitivity to opioids [64]. Previous studies have indicated that chronic morphine ad-
ministration activates ERK 1/2 in the vlPAG [14, 63] and in the VTA [65] of rats, with direct con-
sequences to the antinociceptive and rewarding effects of morphine, respectively. Further, studies
have shown that opioid-induced ERK 1/2 activity in the vlPAG is internalization-dependent [19, 66],
strongly indicating the involvement of β-arrestin. Our study extends this literature by showing that
systemic administration, not just intra-vlPAG, can activate ERK 1/2 in the vlPAG of mice. An in-
teresting observation that has not been shown previously is that we found ERK 1/2 was activated
following acute morphine in males by 44% compared to saline treatment. However, the kinase
was not significantly increased in acute morphine treated females. Previous studies have found that
acute morphine injection into the vlPAG of rats does not activate ERK 1/2 [14]. Our observations
may be attributed to differences in the model organism or route of administration. Further, various
opioids produce differential ERK 1/2 activation within the vlPAG. For instance, pERK 1/2 activa-
tion within the vlPAG occurs following acute DAMGO injections but not following morphine or
fentanyl [14, 19, 67].
Several GPCRs, including MOPr, can continue to signal via β-arrestin after having been lo-
calized to the endosomal compartment following internalization [15, 68]. The phosphorylated C-
terminal tail of the GPCR is located outside the periphery of the clathrin-coated endosome, making
β-arrestin accessible to the cytosolic compartment [69, 70]. Using quantifiable co-localization as-
says, we demonstrated significant overlap of pERK 1/2 and the early endosomal marker Eea1. Taken
together, the increase in pERK 1/2 activity coupled with the elevated co-localization of the kinase
with the endosome leads us to infer that the MOPr in the vlPAG can continue to signal via the
β-arrestin-ERK 1/2 pathway after chronic morphine treatment, a phenomenon that is described in
23
multiple opioid receptors [71, 72].
Our results support the existing hypothesis that following long-term MOPr agonism, there is
a shift in ERK 1/2 activation from a G-protein-dependent pathway to a β-arrestin-dominant system
[13, 67]. Inhibition of ERK 1/2 within the vlPAG increases the magnitude of morphine tolerance
[14], suggesting that its activity is a compensatory measure that counteracts morphine antinocicep-
tive tolerance.
2.4.2 Protein Kinase-C
In the morphine-MOPr system, Protein Kinase-C (PKC) is activated by the βγ subunits of
G-proteins via the phosphoinositide 3-kinase (PI3K) cascade [22, 73]. Activated PKC is known to
phosphorylate the MOPr to facilitate desensitization of the receptor and terminate G-protein signal-
ing following morphine administration [66, 74, 75? ]. Further, as PKC interacts with the MOPr,
the receptor is not rapidly internalized and recycled. This leads to an extended duration where
the receptor is unresponsive to further exposure to morphine. This cellular phenomenon has been
shown to contribute to the reduction in opioid antinociception [12, 76, 77, 78]. Intra-PAG and in-
tracerebroventricular inhibition of PKC has been shown to reduce the development of acute and
chronic tolerance to morphine [47, 79? ], emphasizing the role of the kinase in regulating mor-
phine antinociception. In addition to the behavioral outcomes, PKC inhibitors have been shown to
decrease opioid receptor desensitization in cellular models and interact with ion channels such as
TRPV1 to modulate MOPr activity and antinociception [80, 81]. The current study utilizes antibod-
ies that recognize phosphorylated motifs of conventional PKC subtypes (α, β, and γ). These PKC
isoforms have been demonstrated to mediate morphine tolerance [66, 82], making the assessment of
their activity and localization valuable. While the studies inhibiting PKC were performed in vivo,
many of the fundamental studies evaluating agonist-specific PKC activity were performed in vitro
[83, 84? ]. Here, we use native tissue from a wild-type mouse strain to show that PKC activation
is increased in the vlPAG via phosphorylation of its Ser-Thr sites. We also note that pPKC levels
are not significantly altered after acute morphine treatment in both sexes, but are elevated following
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chronic morphine treatment. In an average cell, chronic morphine treatment increases PKC activa-
tion in males by 102% and in females by 57% compared to the respective sex-specific control. This
pattern suggests an underlying mechanism by which long-term morphine induces elevated PKC
activation within the vlPAG which may contribute to the development of antinociceptive tolerance.
2.4.3 Protein Kinase-A
PKA is a ubiquitous downstream modulator of G protein-coupled receptors that is activated
by the enzyme AC. As a result of activating the MOPr, the inhibitory G-protein that is coupled to
the receptor inhibits AC and PKA activity. In this study, PKA activation was assessed by proxy via
antibodies targeting its phosphorylated substrates as antibodies targeting total PKA would not pro-
vide information about enzyme activity. In our results, we found an interesting localization pattern,
where phosphorylated PKA substrates are a) present in the nuclei of the vlPAG cells and b) altered
in number depending on the duration of morphine exposure. We note that the total pPKA substrate
signal is greatest in our chronic morphine treated mice, with males displaying a 115% increase
and females displaying a 74% increase in PKA activity in the vlPAG compared to the sex-specific
saline controls. Our analysis further shows that these chronic morphine-treated animals also have
the least number of nuclear punctae of pPKA substrate. Sustained morphine treatment in-vitro has
been shown to result in a phenomenon known as cAMP superactivation [21, 85]. This delayed com-
pensatory response to the effects of morphine has been postulated to contribute to opioid tolerance
and dependence [86, 87]. As sustained PKA activity is also directly responsible for maintaining
cellular tolerance to opioids, intervening in cAMP superactivation is a possible avenue to ensure
longer-acting opioid responsiveness. Inhibition of this pathway (AC or PKA) has been shown to
reverse morphine tolerance [10, 47] further implicating that alterations of this signaling pathway
regulates tolerance.
While PKA nuclear translocation has been shown to be facilitated by A-Kinase Interacting
Protein-1 (AKIP1), accounting for PKA activity inside the nucleus [20, 88], we are yet unsure if
this is modulated by opioid receptor agonists. While previous studies that correlate PKA superac-
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tivation with cellular tolerance were performed in-vitro, our results provide a corroboration of the
hypothesis that enhanced PKA activity within the vlPAG is associated with antinociceptive tolerance
to morphine.
2.4.4 Sex-Differences in Morphine Tolerance
In the current study, we have shown that male and female mice develop rapid antinociceptive
tolerance to repeated injections of morphine. This data is similar to what has been shown previ-
ously in rats [89, 90]. Some studies have indicated that female rodents require higher doses of
morphine compared to males to produce equivalent analgesia [91]. We note that in our study, 10
mg/kg morphine produced comparable analgesia in terms of thermal latencies in both males and
females. Previous studies have attributed sex differences in opioid antinociception and tolerance
to differences in MOPr density, number of projections within the descending pathway, microglia
activity, and interactions with estrogen and the estrogen receptor. Here we have taken this a step
farther to show that the molecular correlates of tolerance development to morphine can be attributed
to an increase in pERK 1/2, pPKC, and pPKA substrate signaling in the vlPAG in both sexes.
We note that the males in our study developed antinociceptive tolerance on only the hot plate
but not on the tail flick assay. The hot plate test is a supraspinal measure of nociception, whereas
the tail flick assay is a spinal reflex. We attribute this discrepancy to the differential development
of opioid tolerance as a result of MOPr expression and immune microenvironments at the spinal
and supraspinal levels [92, 93, 94]. Taken together, the spinal cord engages intracellular signaling
pathways and immune responses that differ from that of the vlPAG. The interaction of the immune
microenvironment with opioids such as morphine has been previously reviewed in Ref. [6].
Previous studies have focused on only males to evaluate intracellular kinases after morphine
treatment [14, 63, 95, 96]. To our knowledge, this is the first study to directly compare males to
females using quantification of kinase activity specifically within the vlPAG, which is challenging
to accomplish with conventional protein quantification methods given the size of the vlPAG in mice.
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We note the absence of a significant increase in ERK 1/2 activation in females after acute morphine.
On the other hand, following chronic morphine, females displayed an elevated pERK 1/2 signal
similar to the males. This effect indicates comparable levels of β-arrestin signaling in males and
females after chronic morphine. As this signaling pathway has been associated with internalization
of the receptor [12, 53], this increase in pERK 1/2 activity in females suggests that they are may
display similar levels of receptor internalization as males after chronic morphine treatment. A sum-
mary of the sex differences of each kinase can be found in Table 1.
The current study found no sex differences in the pattern of PKC activity. The absence of a
short-term change in PKC activity levels suggests that while chronic morphine preferentially acti-
vates PKC, acute morphine may engage a different kinase to terminate MOPr signaling. Previous
reports have shown that estradiol does not contribute to MOPr desensitization via PKC in the pres-
ence of the opioid peptide DAMGO [97, 98, 99]. This supports our observation that the presence of
estrogen does not alter morphine- and MOPr-dependent PKC activity.
Female mice show no change in PKA activity after acute morphine treatment, similar to the
effect seen with ERK 1/2 and PKC. Females show superactivation of AC and reduced nuclear trans-
port of phosphorylated PKA substrates only after chronic morphine. On the other hand, male mice
display elevated PKA activity immediately following acute morphine treatment, which remains
steadily elevated through morphine tolerance. This effect can be attributed to the method of chronic
opioid treatment, where morphine injections are repeated by a delay of several hours. This can result
in multiple cycles of cellular withdrawal and subsequently a self-compensatory effect to prevent fur-
ther AC activation. While estradiol and chronic morphine have both been shown enhance hypotha-
lamic PKA activation in guinea pigs [97, 100], it is yet unclear if they both contribute synergistically
to PKA activation within the vlPAG. Further, there is evidence that activated PKA substrates can
localize to distinct intracellular compartments [88]. However, the role of estrogen in mediating
their nuclear transport remains to be established. Current evidence points to immuno-modulatory
effects of morphine and estrogen in contributing to sex differences [91] in opioid effects. The sex
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differences in kinase activity following morphine may also contribute to the behavioral differences
that are commonly seen in morphine antinociception and tolerance. Further studies are required
to collect evidence of cross-talk between the estradiol-estrogen receptor and MOPr-AC signaling
systems in the vlPAG.
In conclusion, our results demonstrate that chronic intermittent morphine treatment results in
the enhanced activation of several protein kinases within the vlPAG that are downstream of the
MOPr in male and female mice. The activation of these kinases can serve to enhance morphine
tolerance (PKC and PKA) or compensate for tolerance (ERK 1/2).
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Supplementary Material: Microscope and Laser Settings




40x/1.40 Oil DIC M27
Pinhole 47µm 47µm
Pixel dwell 1.58 µs 1.58 µs
Z-depth n/a 25 µm
Table 2.2: Equipment settings for 20x and 63x objectives
Laser Settings A594 DAPI A488
Filters 585-734 nm 410-579 nm 495-592 nm
Digital offset (-130) – (-95) (-162) – (-182) (-93) – (-42)
Digital gain 1.0 1.0 1.0
Master gain 911 – 1032 816 770 – 824
Averaging line 8 line 8 line 8
Laser power 2% 2% 2%
Table 2.3: Laser settings for fluorophore detection
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CHAPTER 3
INHIBITION OF PROTEIN KINASE-C WITHIN THE VENTROLATERAL
PERIAQUEDUCTAL GRAY COUNTERACTS THE DEVELOPMENT OF MORPHINE
ANTINOCICEPTIVE TOLERANCE
3.1 Introduction
The midbrain ventrolateral periaqueductal gray (vlPAG) is a component of the descending pain
modulatory system and exerts pro- or anti-nociceptive effects following input from higher cerebral
centers. It is of particular interest in the study of pain systems as it is a site of action of endogenous
and exogenous mu opioid agonists. Additionally, the vlPAG governs the development of opioid
antinociceptive tolerance, a phenomenon where repeated administration of an opioid ceases to pro-
duce adequate pain relief. Tolerance results in a necessity to escalate the dose of the opioid admin-
istered, leading to deleterious side effects such as dependence and addiction.
Current efforts to understand opioid action in the vlPAG include studies that characterize intra-
cellular signaling cascades within this brain region. Opioid painkillers, such as morphine, bind to
µ-opioid receptors (MOPr) in the vlPAG. Following repeated opioid exposure, multiple cellular and
molecular adaptations occur within this brain region, which can be interpreted as molecular signa-
tures of behavioral changes. Intracellular kinases that participate in the MOPr signaling pathway are
of particular interest since manipulation of MOPr-downstream kinases can indeed have behavioral
outcomes.
Previous in vitro studies have shown that PKC phosphorylates Ser-Thr sites in the activated
MOPr, leading to desensitization of the receptor [23, 24]. PKC-dependent desensitization has been
shown to be the predominant cellular mechanism when the MOPr is stimulated by morphine, but
not high-potency agonists. These studies hypothesize that this particular mechanism is inefficient at
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enabling rapid MOPr internalization and recycling to the membrane, thereby contributing to mor-
phine tolerance in vitro [83]. However, whether PKC interacts with MOPr after morphine agonism
within the vlPAG in vivo is unknown.
PKC is also of particular interest within the MOPr pathway in vivo. The kinase has been
shown to interact with µ, δ, and κ opioid receptors to modulate stress and analgesia behaviors
across different brain regions [82, 101, 102]. In particular, PKC activity has been shown to en-
able antinociceptive tolerance towards partial MOPr agonists such as morphine. Conversely, PKC
is ineffective at reducing tolerance to repeated administrations of the more potent MOPr agonist,
DAMGO [24, 103]. While previous studies on PKC have inhibited conventional PKC isoforms in
the CNS to modulate behavioral morphine tolerance, the specific role of PKC within the vlPAG to
modulate this effect has not been described [104].
We hypothesize that Protein Kinase-C activity in the vlPAG plays a critical role in the devel-
opment of morphine antinociceptive tolerance. We found that repeated inhibition of PKC specifi-
cally within the vlPAG prevents the development of morphine tolerance. In addition, we note that
inhibition of PKC activity within the vlPAG enhances the antinociceptive effect of morphine in
opioid-naı̈ve mice. Our findings establish that PKC activity within the vlPAG contributes to the
development of morphine antinociceptive tolerance.
3.2 Materials and Methods
3.2.1 Animals
Adult male C57BL/6 mice (Charles River Laboratories, CA), 6-8 weeks old and weighing 18-
26 g at the start of the study were used in the study. Food and water were available ad libitum, except
during testing. Mice were housed (four to five per cage) in a humidity and temperature-controlled
room with a 12-hour light/dark cycle (off at 1900). All procedures were performed in accordance
with the Guide for the Care and Use of Laboratory Animals adopted by the National Institutes
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of Health and were approved by the Institutional Animal Care and Use Committee of Utah State
University (Protocol no. 2775).
3.2.2 Drugs
Morphine sulphate (West Ward, Inc.) was obtained as 8 mg/ml stock and different dosages (10,
8, 4.4, 2 & 1 mg/kg) were prepared by diluting with sterile 0.9% saline. Go-7874 (Cat. 365252,
Sigma-Aldrich) was dissolved in 10% DMSO and 16nmols were cumulatively administered per
animal over 8 microinjections. This particular concentration of the PKC inhibitor was selected as
it was previously shown to prevent the development of morphine tolerance when injected into the
cerebrospinal fluid [47]. Animals were pre-treated by microinjection of either the PKC inhibitor
or DMSO vehicle (0.2 µl/session) 15 mins prior to systemic injection of morphine (10mg/kg) or
saline. This dose of morphine was selected as it has been reported to produce rapid antinociceptive
tolerance after repeated injections [40].
3.2.3 Stereotaxic surgery
Briefly, animals were anaesthetized with a mixture of ketamine (100 mg/ml) and xylazine (20
mg/ml, Akorn, Inc.) in sterile 0.9% saline, injected intraperitoneally (i.p.) at a dose of 10 ml/kg. The
animal was then placed in a stereotaxic apparatus (Stoelting and Kopf). The skull was exposed by
an incision of the scalp followed by application of povidone iodide (Betadine). A small craniotomy
was made using a hand drill at the region of interest. Stereotaxic coordinates (AP: -4.8, DV: -0.6,
ML:-2.3 from bregma) as described previously [56, 105] were used to lower the guide cannula into
the vlPAG. Two small bone anchor screws (Cat. 51457, Stoelting) were implanted away from the
cannulation site to provide support for the cranial plaster (Stoelting). A stylet was placed in the
implanted cannula to prevent blockage. Guide cannula (4 mm) and stylets (4 mm) were made in-
house using a 25g syringe needle (Exel Inc.) and a metal wire (Small Parts, Inc.) respectively.
Injectors to deliver the drug through the guide cannula were made in-house using a metal wire
(Small Parts, Inc) trimmed to a length of 5 mm, which is 1 mm beyond the guide cannula. Mice
were placed in a clean cage near a gentle heat source until recovered from anesthesia and then pair-
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housed housed in the animal facility. Their health was monitored by assessing grooming and weight
daily during the course of their recovery and behavioral testing. Behavioral tests were performed
after at least 10 days of recovery. At the conclusion of the behavioral study, cresyl violet (Sigma)
was microinjected into the cannula and animals were euthanized by CO2 inhalation. The animals’
brains were isolated, sectioned to 100 um thickness on a vibratome (Leica) and microinjection
location was examined using a brightfield microscope (Keyence BZ-X810).
3.2.4 Intra-vlPAG microinjection
Over the course of recovery from stereotaxic surgery, animals were handled daily to acclimatize
them to the experimenter and to prevent occlusion of the cannula by fluid clots. For microinjection of
the PKC inhibitor or vehicle, animals were gently restrained and the injector was lowered through
the guide cannula. The injector was set up to be connected to a 1µl syringe (Hamilton) using
flexible tubing. The syringe plunger was depressed at a rate of 0.1µl/30s for a total of 0.2µl/session.
Following microinjection of the appropriate volume of drug or control solution, the injector was left
in place for another 30s to prevent backflow.
3.2.5 Behavior testing
Following complete recovery from surgery, mice were tested on the hot plate and tail flick
assays to obtain their baseline thermal nociceptive thresholds. On Day 1 of the study, the effect of the
PKC inhibitor on acute morphine administration was assessed. Briefly, following pre-treatment with
Gö-7874 or 10% DMSO, animals were injected with either morphine (10mg/kg, i.p.) or 0.9% saline
(10ml/kg, i.p.). 30m following the morphine or saline treatment, the animals’ thermal latencies were
assessed on the hot plate and tail flick tests. The animals were not subjected to further behavioral
tests until Day 5. On Day 5 of the study, the animals were subjected to a morphine dose-response
paradigm, during which the subjects were challenged with log-normal increasing doses of morphine
and tested on their thermal nociceptive thresholds.
3.2.6 Immunofluorescence staining and confocal microscopy
Immunofluorescence staining was performed as described previously [40]. Briefly, the mice
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were deeply anesthetized using isofluorane and transcardially perfused with 4% paraformaldehyde
(PFA). Their brains were post-fixed in 4% PFA for 1 hour following which they were stored in
1x PBS until further processing. Sectioning was performed on a vibratome (Leica Biosystems,
Germany) and 50 µm sections containing the vlPAG were selected for immunofluorescence analy-
sis. The sections were first incubated in sodium borohydride (1% in PBS) to expose the epitopes
and reduce autofluorescence caused by the fixative. Subsequently, they were permeabilized with
Triton-X 100 (Sigma-Aldrich, St. Louis, MO), blocked with normal goat serum (5% in PBS), and
incubated overnight in primary antibodies in their appropriate buffer [1% BSA (Sigma) and 3%
Triton X-100 (Sigma) in PBS]. The following day, the slices were washed in PBS and incubated for
2 hours in diluted secondary antibodies in 1% BSA in PBS. The antibodies were sourced from Cell
Signaling Technology (Rabbit anti-pPKC Cat. 38938S 1:400), Neuromics (Guinea Pig anti-MOPr
Cat. GP10106 1:200) and Life Technologies (Goat anti-Rabbit A594 Cat. A11037 1:1000; Goat
anti-Guinea Pig A647 Cat. A21450 1:1000). Following a second incubation with the fluorophore-
conjugated antibody and subsequent PBS washes, the slices were briefly (5 mins) incubated in
DAPI, washed with PBS and mounted with an anti-fade (ProLong Diamond Anti-Fade, Life Tech-
nologies) on a glass slide. Confocal images of coronal sections comprising of the rostrocaudal axis
of the vlPAG as, defined by the mouse brain atlas [56], were acquired on a Zeiss LSM 710 confocal
microscope (Carl Zeiss Microscopy, Germany) at Utah State University’s microscopy core facility.
3.2.7 Quantification of fluorescence intensity and signal overlap
Fluorescence intensities of individual kinases were calculated from unedited images while cor-
recting for local background fluorescence. Briefly, for each image of the vlPAG hemisphere that
was analyzed, 10 regions corresponding to either pPKC or MOPr were selected that encompass
the entire cell body. Three regions corresponding to local background were also selected for each
image. This process was performed for the left and right vlPAG hemispheres and repeated across
three coronal sections per subject. Each IHC image containing one hemisphere of the vlPAG was
analyzed as an independent measurement to account for the structural and functional heterogeneity
of the PAG columns [57, 58, 59] in addition to controlling for the laterality of antinociception in the
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PAG [60, 61]. We broadly assessed kinase activation in the vlPAG without filtering cell-type speci-
ficity, as was performed previously [62, 63]. Following automated image thresholding, fluorescence
intensities and relevant parameters were measured with ImageJ (NIH). The corrected total cell flu-
orescence (CTCF) was calculated for each cell from the integrated density measurement using the
formula: CTCF = Integrated Density – (Area of selection x background mean fluorescence). The
fluorescence intensities were measured in Arbitrary Units (AU).
For statistical analyses, average CTCF values of each image in a treatment group were nor-
malized to the average of the saline control group of the specific sex using the formula: Y = [(Y-
K)/K]*100, where Y is the individual data point and K is the overall average of the saline group
for the particular sex and kinase. As there were differences in the saline groups between males and
females, we performed this normalization to better compare morphine-induced kinase activity. Co-
localization of pERK 1/2 and Eea1, imaged using red and green fluorescent channels respectively,
was represented as the Pearson’s correlation coefficient and was calculated using the JACoP plugin
in ImageJ. This was done in order to automate the analysis in an unbiased manner. The plugin mea-
sures overlap between the red and green fluorescent channels with the Pearson’s coefficient (r) being
the output. A coefficient of 1 is indicative of total overlap while a coefficient of 0 implies no overlap.
This method to quantify colocalization of Eea1 with other proteins has been used previously using
immunofluoresence in cells [62]. Representative images from all experiments were processed using
the Iterative Deconvolve 3D macro in ImageJ to enhance signal and remove fluorescent artifacts.
All images were processed through 5 deconvolution cycles.
3.2.8 Statistical Analysis
Results are presented as mean ± standard error of mean (SEM). Statistical analyses of behav-
ioral studies were performed using a repeated measures two-way analysis of variance (ANOVA)
combined with Bonferroni’s post-hoc test. Ninety-five percent confidence intervals (CI) were used
to compare individual ED50 values following a significant ANOVA. Statistical analyses of qRT-
PCR data and fluorescence quantification were performed using a one-way ANOVA combined with
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a Tukey’s post-hoc test. Normality of data was evaluated using the D-Agostino and Pearson test.
Experimenters were not blinded to drug treatment over the course of the study. Morphine treatment
produces marked hyperlocomotion in mice and Gö-7874 possesses a strong orange hue, making
blinding impractical for the experimenter. All graphing and statistical analyses were performed
using Prism 9.0 (GraphPad, San Diego, CA).
3.3 Results
3.3.1 Activated Protein Kinase-C is co-localized with the µ-opioid receptor in the
ventrolateral PAG following morphine tolerance
Previous in vitro studies have suggested that morphine-induced activation of the MOPr causes
recruitment of PKC to the receptor for phosphorylation. Receptor phosphorylation results in the
termination of G-protein signaling and is considered to be the first step in receptor desensitization
and internalization. In order to determine if PKC associates with MOPr in the vlPAG following
morphine treatment, we performed co-staining for pPKC and MOPr in brain slices of mice treated
with acute or chronic morphine (Fig. 3.1A). We quantified the intensity of MOPr fluorescence in the
vlPAG of saline, acute morphine, and chronic morphine treated animals. A one-way ANOVA indi-
cated significant differences in MOPr fluorescence intensity between these treatment groups (F(2,
149) = 16.15, p<0.0001). A Tukey’s post-hoc analysis revealed that the fluorescence signal intensity
is highest in chronic morphine-treated animals (Saline vs Chronic Morphine p<0.0001; Acute Mor-
phine vs Chronic Morphine p<0.001; Fig. 3.1B, C). This indicates that following chronic morphine,
there appears to be an increase in the protein levels of the MOPr in the vlPAG. We then analyzed the
overlap between the two pPKC and MOPr signals and computed a Pearson’s correlation coefficient.
A non-parametric comparison of the signal overlap score indicated significant differences between
the median scores of the groups (Kruskal-Wallis test, p<0.0001). A Dunn’s multiple comparisons
analysis revealed that the median difference in signal intensity is higher in chronic morphine treated
animals (Saline vs Chronic Morphine, p<0.0001; Acute Morphine vs Chronic Morphine, p<0.01),
indicating that the activated PKC is associated with the MOPr to a greater degree in these mice (Fig
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Fig. 3.1: Activated Protein Kinase-C is co-localized with the µ-opioid receptor in the ventrolat-
eral PAG following morphine tolerance. (A) Representative 20x images of the vlPAG stained for
pPKC (green), MOPr (magenta) and DAPI (blue) (B) Quantification of immunofluorescence sig-
nal from MOPr. (C) Quantification of signal overlap between pPKC and MOPr channels. One-way
ANOVA with Bonferroni’s post-hoc test and Kruskal-Wallis test with Dunn’s multiple comparisons,
∗∗p<0.01, ∗ ∗ ∗p<0.001, ∗ ∗ ∗∗p<0.0001. Scale bar = 50µm
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3.1B, D).
3.3.2 Acute Protein Kinase-C inhibition does not affect morphine antinociception
We proceeded to locally inhibit PKC activity by unilaterally implanting a cannula over the
vlPAG to deliver the PKC inhibitor, Gö-7874 (see Fig. 3.2A for a timeline). Only mice that had
injection sites located within or directly adjacent to the ventrolateral PAG were included in analysis
as good placements (Fig. D) In order to assess if acute inhibition of PKC had any effect on the
antinociceptive effect of morphine, we tested the mice on the hot plate and tail flick assays following
the microinjection and drug treatment. A two-way ANOVA indicated significant differences in
thermal latencies in both the hot plate (Time F(2, 33.23) = 287.3, p<0.0001; Treatment F(3, 17) =
17.45, p<0.0001; Time x Treatment F(6,34) = 94.85, p<0.0001) and tail flick (Time F(2, 22.74)
= 55.89, p<0.0001; Treatment F(3, 18) = 9.01, p<0.0001; Time x Treatment F(6,36) = 15.63,
p<0.0001) tests. A Tukey’s post-hoc analysis of the hot plate or tail flick tests revealed that there
were no differences in thermal latencies between treatment groups prior to the commencement of
the PKC inhibition paradigm (p>0.05). The post-hoc analysis also revealed that following acute
morphine treatment, the thermal latencies of the mice were significantly different compared to the
baseline of the respective group in both the hot plate and tail flick tests (Tukey’s p<0.05). However,
there were no differences in thermal latencies on the hot plate or tail flick tests between groups that
were pre-treated with Vehicle or Gö-7874 (Tukey’s p>0.05). Thus, acute treatment with the PKC
inhibitor, Gö-7874 does not alter the antinociceptive effects of morphine, producing comparable
antinociception as the Vehicle control.
3.3.3 Inhibition of Protein Kinase-C within the vlPAG prevents the development of
morphine antinociceptive tolerance
On Day 5 of the study, the development of morphine tolerance was assessed in mice. Baseline
hot plate and tail flick latencies were measured prior to the morphine dose-response test. A one-way
ANOVA indicated that on Day 5 of the study, the thermal threshold baselines of the groups were
not significantly different from each other on both the hot plate (F(3, 19) = 2.99, p>0.05) and tail
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Fig. 3.2: Acute Protein Kinase-C inhibition does not affect morphine antinociception. (A) A picto-
rial timeline of the intra-vlPAG PKC inhibition paradigm. (B) Hot plate and (C) Tail flick latencies
of mice on Day 1 of the study. The mice were first microinjected with the PKC inhibitor or vehicle.
15 minutes later, they were given a subcutaneous injection of morphine or saline. Acute antinoci-
ceptive effects of morphine were tested 30 mins after the s.c. injection. (D) Representative images
of the rostro-caudal axis of the ventrolateral PAG depicting intra-vlPAG cannula placements.
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Fig. 3.3: Inhibition of Protein Kinase-C within the vlPAG prevents the development of morphine
antinociceptive tolerance. (A) Hot plate and (B) Tail flick baselines prior to the morphine dose-
response test. (C) Hot plate and (D) Tail flick latencies of mice over the course of a morphine
dose-response to test the development of antinociceptive tolerance.
flick (F(3, 19) = 0.38, p>0.05) tests. Repeated morphine treatment caused a significant rightward
shift in the morphine dose-response curve on Day 5 on the hot plate (F(3, 117) = 32.9; Fig. 3.3C)
and the tail flick (F(3, 117) = 9.63; Fig. 3.3D ) tests, indicating the development of antinociceptive
tolerance. Repeated pre-treatment of the Protein Kinase-C inhibitor, Gö-7874, preceding each mor-
phine injection did not cause this rightward shift, revealing that PKC inhibition within the vlPAG
prevented the development of morphine antinociceptive tolerance. This is numerically quantified as
measured by the ED50 values of morphine on the hot plate and tail flick tests (see Table 3.1). Fur-
ther, pre-treatment with Gö-7874 enhanced morphine antinociception, producing a leftward shift in
morphine-naı̈ve mice compared to vehicle-treated controls in both hot plate and tail flick tests (Fig.
3.3 C and D; Table 3.1).
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Hot Plate 5.45 ±0.61# 21.01 ±4.81∗ 3.02 ±0.33∗# 6.5 ±0.74#
Tail Flick 13.19 ±2.44# 30.59 ±7.51∗ 7.59 ±1.12∗# 13.97 ±2.95#
Table 3.1: ED50 values for morphine on the hot plate and tail flick test after intra-vlPAG microinjec-
tion. Data are presented as Morphine ED50 values ± C.I. (mg/kg). * - statistically significant from
vehicle + saline, # - statistically significant from vehicle + morphine; C.I.: confidence interval.
Fig. 3.4: Non-vlPAG inhibition of Protein Kinase-C does not prevent the development of morphine
antinociceptive tolerance. (A) Hot plate and (B) Tail flick latencies of mice over the course of a
morphine dose-response to test the development of antinociceptive tolerance.
3.3.4 Non-vlPAG inhibition of Protein Kinase-C does not prevent the development
of morphine antinociceptive tolerance
We sought to determine the specific role of the vlPAG in modulating PKC-dependent morphine
antinociceptive tolerance. Following morphine dose-response testing on Day 5, cannula implanta-
tion sites were visualized. Mice that had non-vlPAG directed injection sites were grouped according
to their treatment groups and were analyzed separately. Mice pre-treated with Vehicle + Morphine
displayed a significantly higher rightward shift in the dose response curve on the hot plate (Fig.
3.4A) and tail flick (Fig. 3.4B) tests, indicative of the development of antinociceptive tolerance. An
analysis of variance indicated significant differences in ED50 values of morphine in the hot plate
(F(3, 88 = 6.73, p<0.001) and tail flick test (F(3, 88) = 3.71, p<0.05). On the hot plate and tail flick
tests, there were no significant differences between the morphine ED50 values for Vehicle + Saline
treated mice and the Gö-7874 + Saline treated mice (see Table 3.2). This indicates that non-vlPAG
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targeted microinjection of PKC inhibitor did not enhance morphine antinociception in opioid-naı̈ve
mice. Further, there were no significant differences between the morphine ED50 values of the Vehi-
cle + Morphine treated mice and the Gö-7874 + Morphine treated mice (Table 3.2). This indicates
that non-vlPAG targeted microinjection of the PKC inhibitor did not prevent the development of
antinociceptive tolerance to morphine in this group of mice.






Hot Plate 4.69 ±1.09# 18.44 ±3.34∗ 5.85 ±1.5# 10.12 ±0.97∗#
Tail Flick 9.40 ±0.93# 19.13 ±4.27∗ 9.38 ±2.08# 16.86 ±2.77∗
Table 3.2: ED50 values for morphine on the hot plate and tail flick test after non-targeted intra-
vlPAG microinjection. Data are presented as Morphine ED50 values ± C.I. (mg/kg). * - statisti-
cally significant from vehicle + saline, # - statistically significant from vehicle + morphine; C.I.:
confidence interval
3.4 Discussion
In this current study, we found that MOPr receptor immunostaining is increased after morphine
tolerance and it is co-localized with phosphorylated PKC. Inhibition of PKC activity within the ven-
trolateral periaqueductal gray (vlPAG) reduces the development of tolerance to the antinociceptive
effects of morphine. Further, microinjection of the PKC inhibitor, Gö-7874, within this brain region
enhances the antinociceptive effect of morphine in opioid-naı̈ve animals. Taken together, this study
demonstrates the importance PKC activity within the PAG in driving morphine antinociceptive tol-
erance.
The PAG is a highly heterogeneous brain region divided into distinct spatial regions with spe-
cialized functions. The vlPAG encompasses the greatest number of neurons that project to the
medulla and modulate descending pain. As a region enriched in MOPr, this brain region is a key
component of endogenous opioid signaling. In addition to its role in channeling antinociceptive in-
put to medulla, the vlPAG is also independently capable of producing antinociception via electrical
or pharmacological stimulation. Interestingly, repeated pharmacological stimulation of the vlPAG
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via microinjection of opioid agonists can produce antinociceptive tolerance as measured by a de-
crease in potency and efficacy of the agonist [106]. Thus, the vlPAG is a critical gatekeeper in the
continued efficacy of opioids in pain relief and repeated opioid receptor activity in this brain region
is a contributor to antinociceptive tolerance. In order to validate advances in pain therapeutics, we
require a precise understanding of the mechanisms by which adaptations in the vlPAG contribute to
macroscopic behavioral changes following opioid tolerance.
The development of morphine antinociceptive tolerance can also occur following repeated sys-
temic injection of morphine [6]. On acute pain tests, this is manifested as a reduction in latency
compared to opioid-naı̈ve mice to thermal noxious stimuli following repeated treatment with the
opioid. While electrophysiological and behavioral studies have examined the contribution of the
PAG in morphine antinociceptive tolerance, the contribution of intracellular signaling kinases to-
wards this effect has not been fully clarified [10, 19]. Protein Kinase-C is a particularly interesting
candidate for inquiry into the intracellular mechanisms of morphine tolerance as it is reported to
phosphorylate the morphine-activated MOPr and contributes to its delayed internalization and recy-
cling in a cellular model [83].
The appearance of pPKC around the periphery of vlPAG neurons co-localizing with MOPr
suggests that the kinase is actively phosphorylating the receptor following morphine agonism. This
result has been previously shown in vitro where phosphorylation-deficient PKC was unable to
associate with the MOPr after morphine-stimulation (REF). Further, electrophysiological studies
looking at rat Locus Ceuruleus neurons have indicated that PKC-dependent phosphorylation of the
MOPr produces desensitization of the receptor, contributing to opioid tolerance [81]. Interestingly,
while there is a reported loss of function of the MOPr following morphine tolerance, our immunoflu-
orescence data indicates that the protein levels are increased specifically within the vlPAG. Previous
studies have suggested a down-regulation of MOPr protein levels in the mouse brainstem and in cell
culture following opioid tolerance [107, 108]. However, other studies have shown an upregulation
of MOPr mRNA across the brain including within in the PAG and an enhancement in MOPr lev-
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els at forebrain synaptic sites [109, 110]. Our observation is in agreement with these latter reports
suggesting that within the PAG, morphine tolerance over 5 days produces an upregulation of MOPr
protein levels that is associated with activated conventional isoforms of PKC.
PKC exists in multiple isoforms, including conventional and atypical isoforms. While these
are all expressed in the central nervous system [82], we elected to apply the conventional isoform
inhibitor, Gö-7874. Previous studies using this inhibitor have shown that intra-cerebroventricular
injection of this compound can reinstate antinociception in morphine pelleted mice [82, 111]. In
addition, a study using a non-specific GRK/PKC inhibitor within the vlPAG blocks morphine tol-
erance development [18]. Several leading hypotheses propose that PKC works endogenously to
produce tolerance to morphine [112]. The desensitization of the morphine-activated MOPr through
PKC-dependent phosphorylation is not a strong recruiter of the internalization system. As the recep-
tor recycling lags behind, other systems step in to produce intracellular adaptations, one of which
manifests as behavioral tolerance to the antinociceptive effects of opioids [113]. Our work expands
on these studies and implicates the conventional PKC isoforms within the vlPAG in regulating mor-
phine tolerance.
The ED50 of morphine is varied across the hot plate and tail flick tests, indicating differences
in supraspinal and spinal antinociception. An interesting divergence in the physiology of morphine
tolerance emerges when comparing the hot plate and tail flick morphine ED50 values in the Ve-
hicle + Morphine treated mice (Table 3.1. It appears that to achieve equivalent antinociception at
the spinal level as measured by the tail flick test, a 10-fold higher dose of morphine is needed in
comparison to supraspinal antinociception as measured by the hot plate test. Previous studies have
indeed noted a higher dose of morphine is required to produce equivalent antinociception on the tail
flick test compared to the hot plate, attributable to both the route of delivery of the opioid and the
local density of opioid receptors [82].
A remarkable outcome of this study is the observation that repeated treatment with the PKC
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inhibitor in opioid-naı̈ve mice resulted in a significant decrease in the ED50 of morphine on the hot
plate test. This suggests that preemptive inhibition of PKC activity can enhance the antinociceptive
ability of morphine at both the spinal and the supraspinal levels. It can be hypothesized that PKC
inhibition in the vlPAG contributes to the enhancement of morphine antinociception in opioid naı̈ve
mice, while preventing the development of morphine tolerance in mice treated chronically with the
opioid. This observation also raises interesting questions about the distribution of PKC expression
in the CNS and their relative contribution to the development of opioid antinociceptive tolerance,
which is deserving of further investigation.
The development of opioid tolerance is particularly deleterious in clinical considerations as
the physician must increase the prescribed dose of opioid to achieve desired levels of pain relief,
placing the patient at an increased risk for developing opioid use disorder. Here, we show that
the antinociceptive tolerance to morphine is regulated by the kinase PKC within the ventrolateral
periaqueductal gray. Further research into the mechanisms of PKC activity within the vlPAG are
needed to decouple the effects of antinociceptive tolerance and morphine dependence. In addition,
as females have been reported to develop a lesser degree of antinociceptive tolerance than males
[114], the contribution of PKC activity to these sex differences also warrants exploration.
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CHAPTER 4
GPR171 ALLEVIATES CHRONIC NEUROPATHIC AND INFLAMMATORY PAIN IN MALE,
BUT NOT FEMALE MICE
4.1 Introduction
Chronic pain is growing public health concern with over 50 million adults in the United States
having suffered from the condition since 2016 [115]. Globally, nearly 2 billion people have been
affected by chronic pain conditions, emphasizing the need for extensive research and development
of efficacious therapeutics [116]. Despite the progress made in studying the causal and therapeutic
mechanisms of chronic pain, the inclusion of female cohorts in pain studies is limited [31, 117].
Several reports have highlighted the existence of sex differences in the pathology of chronic pain
[118, 119, 120, 121]. Indeed, females have been reported to experience more severe and persis-
tent pain than males in postoperative settings leading to reduced levels of physical activity [122].
In addition, the estrus stage of females has also been implicated in their pain sensitivity and their
responsiveness to opioid analgesics [91, 123]. However, the long-term use of opioid analgesics for
the treatment of chronic pain has profound negative side effects and has been shown to have limited
effectiveness in the daily management of chronic pain [27]. Given these substantial issues with
usage of opioids, we sought to look beyond this class of drugs to identify efficacious therapeutics
for chronic pain.
G-protein coupled receptors (GPCRs) and their dysregulation is implicated in a wide range of
pathologies, including chronic pain [124, 125, 126]. However, only 34% of FDA-approved drugs
target GPCRs, highlighting the yet untapped potential of the GPCR family to be therapeutic targets
[127, 128]. One particularly promising target of interest for novel pain therapeutics is the G-protein
coupled receptor, GPR171, and its endogenous ligand, BigLEN. The peptide BigLEN is derived
from the neuropeptide precursor ProSAAS. The precursor peptide, in turn, has been shown to be
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upregulated in the cerebrospinal fluid of patients with fibromyalgia and within the periaqueductal
gray in a rodent model of opioid-induced hyperalgesia [129, 130]. The receptor, GPR171, and its
endogenous ligand, BigLEN, are widely expressed through the brain including the periaqueductal
gray (PAG) [40, 131]. This particular brain region is situated in the descending pain modulatory
pathway and is a site of action for a range of antinociceptive drugs including opioids and cannabi-
noids [132, 133]. Previous studies exploring the role of GPR171 in acute pain showed that agonism
of the receptor via systemic administration of the synthetic agonist, compound MS15203, led to an
increase in the antinociceptive effect of systemic morphine administration [40].
We explored the role of GPR171 in chronic neuropathic and inflammatory pain in male and
female mice. The therapeutic potential of the GPR171 agonist compound, MS15203, was assessed
via repeated once-daily systemic (10 mg/kg i.p.) injections. We found that the compound MS15203
reduced the duration of chronic neuropathic and inflammatory pain in male mice, but not female
mice. While we found no alterations in gene expression levels of ProSAAS or GPR171 in the PAG
of male or female mice, we found that CIPN produces a decrease in GPR171 protein levels in vlPAG
of male mice. We note that following MS15203 treatment, the GPR171 protein levels in male mice
with neuropathic pain recovered and were indeed elevated compared to untreated controls. Our
findings demonstrate a sexually dimorphic receptor system in chronic pain and establish a role for
the recently deorphanized receptor GPR171 in the reduction of chronic pain in male mice.
4.2 Materials and Methods
4.2.1 Animals
102 Adult male and female C57BL/6CS mice (Charles River Laboratories, CA), 6-8 weeks
old and weighing 18-26 g at the start of the study were used in the study. Food and water were
available ad libitum, except during testing. Mice were housed (four to five per cage) in a humidity
and temperature-controlled room with a 12-hour light/dark cycle (off at 1900). All behavior testing
took place during the light cycle. For the female cohorts, estrus stage was determined by obtaining
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a vaginal lavage daily starting 5 days prior to the start of the study. A lavage was also obtained
daily over the course of the study. All procedures were performed in accordance with the Guide
for the Care and Use of Laboratory Animals adopted by the National Institutes of Health and were
approved by the Institutional Animal Care and Use Committee of Utah State University (Protocol
2775).
4.2.2 CFA-induced inflammatory pain
Animals were very briefly anesthetized with isofluorane (99.9%, inhaled; Fluriso, VetOne)
and restrained in order to access the plantar surface of the hind paw. Complete Freund’s Adjuvant
(CFA, Cat.F5881, Sigma-Aldrich) was injected under the epidermis into the plantar surface of both
hind paws using a 27G needle (20 µl/paw) as described previously [134]. Animals in the control
group received light isofluorane anesthesia alone without manipulation of their hind paws to prevent
inflammation from the injection procedure. Drug administration commenced 24h following CFA
injection.
4.2.3 Assessment of inflammatory pain in mice
A plantar test was performed as previously described [135] to assess inflammatory pain. Briefly,
the subjects were placed in plexiglass enclosures on top of a glass platform. The animals were ac-
climatized to the testing chamber for 3 days prior to the start of the study (1 hour/session). On each
testing day, the animals were acclimatized in the testing chamber for 20 minutes, or until cessation
of exploratory behavior. A radiant heat source (IITC, Cat. 390) was applied to the plantar surface
of the hind paw and the time to a nocifensive response was recorded. A cut-off time of 20 seconds
was enforced to avoid potential injury due to tissue damage. Two trials were performed on each
hindpaw to obtain the average reaction time per paw and a third reaction time was obtained if the
preceding two values differed by 2s or more. Both left and right hindpaws were tested and their
average thermal latency was considered for statistical analysis. Baseline latencies were established
prior to injection of CFA. Following CFA injection on Day 0, the plantar test took place on Days 1,
3, and 5, where Day 0 marks the injection of CFA and Day 1 is 24h following CFA injection.
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4.2.4 Chemotherapy-induced peripheral neuropathy
Paclitaxel (Sigma-Aldrich, MO, USA) was diluted in a vehicle comprising of Cremphor (Sigma-
Aldrich, MO, USA)/90% ethanol/ 0.9% saline in a 1:1:18 ratio, and administered intraperitoneally
(i.p.; 4 mg/kg) to mice on four alternate days (cumulative dose 16 mg/kg) to induce neuropathy
as described previously [33, 136]. The control group received four injections of the vehicle (10
mL/kg). As paclitaxel can be present in animal excreta, bedding of mice used in this study was
treated as a biohazard and disposed according to University guidelines.
4.2.5 Assessment of mechanical allodynia in mice
The von Frey filament test was performed as previously described [33] to assess allodynia
in mice. Briefly, all mice (vehicle- and paclitaxel-treated) were placed in plexiglass enclosures
mounted onto a testing platform containing a metal, perforated floor (Stoelting Co., Wood Dale, IL,
USA). Animals were acclimatized to the testing chamber for 3 days prior to the start of the study
(1 hour/session). On each testing day, the animals were acclimatized in the testing chamber for 20
minutes, or until cessation of exploratory behavior. Mechanical allodynia was assessed in male mice
by applying von Frey filaments to the midplantar region of both hindpaws for approximately 2s per
stimulus using calibrated filaments (Touch Test kit, Cat.NC12775-99, North Coast Medical). All
trials began with the 1g filament and proceeded using an up-down trial design. Both right and left
hindpaws were tested and their average mechanical threshold was considered for statistical analysis.
A sudden paw withdrawal, flinching, or paw licking was regarded as a nocifensive response. A
negative response was followed by the use of a larger filament. For assessment of mechanical
allodynia in females, an electronic von Frey device (Ugo Basile, Italy; Cat.38450) was used as
the allodynic females’ mechanical thresholds were lower than the detectable range of the manual
filaments. Paw mechanical withdrawal thresholds are expressed as a percentage of baseline values,
where the baseline represents von Frey thresholds prior to paclitaxel or vehicle treatment.
4.2.6 Drug treatment
GPR171 agonist (MS15203, a gift from Dr. Sanjai Pathak) was dissolved in sterile 0.9% saline
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(1 mg/ml). Mice in the Paclitaxel- and CFA-induced chronic pain studies were randomly assigned,
by block randomization, into four treatment groups: pain + MS15203, pain + saline, no pain +
MS15203, and no pain + saline. Mice in the MS15203 treatment group received 10 mg/kg i.p.
as this dose was previously shown to produce an increase in hot plate thermal latency when co-
administered with morphine [40]. To evaluate the effect of MS15203 on chronic neuropathic pain,
the animals were administered with one dose of either MS15203 or saline, once daily for 5 days
starting on Day 15. To evaluate the effect of MS15203 on chronic inflammatory pain, the animals
were administered with one dose of either MS15203 or saline, once daily for 5 days starting 24h
following induction of inflammatory pain.
4.2.7 Immunofluorescence staining and microscopy
Immediately following the final behavioral testing, a subset of the subjects ( 3/group) were
deeply anesthetized using isofluorane and transcardially perfused with 4% paraformaldehyde (PFA).
Their brains were post-fixed in 4% PFA for 1 hour and then were stored in 1x PBS at 4°C until fur-
ther processing. Sectioning was performed on a vibratome (Leica Biosystems, Germany) and 50
µm sections containing the vlPAG were selected for immunofluorescence analysis. The sections
were first incubated in sodium borohydride (1% in PBS) to expose the epitopes and decrease aut-
ofluorescence from aldehydes. Subsequently, they were permeabilized with Triton-X 100 (3%,
Sigma-Aldrich), blocked with normal goat serum (5% in PBS), and incubated overnight in primary
antibodies in their appropriate buffer (1% BSA (Sigma-Aldrich) in PBS). The following day, the
slices were washed in PBS and incubated for 2 hours in diluted secondary antibodies in 1% BSA in
PBS. The antibodies were sourced from GeneTex (Rabbit anti-GPR171, Cat.GTX108131, 1:400)
and Life Technologies (Goat anti-Rabbit A594, Cat.A11037, 1:1000). Following subsequent PBS
washes, the slices were briefly (5 mins) incubated in DAPI, washed with PBS and mounted with an
anti-fade (ProLong Diamond Anti-Fade, Cat.P36961, Invitrogen) on a glass slide. Representative
images of coronal sections containing the vlPAG, as defined by the mouse brain atlas [56], were
acquired on a Zeiss LSM 710 confocal microscope (Carl Zeiss Microscopy, Germany) at Utah State
University’s microscopy core facility.
50
4.2.8 Quantification of immunofluorescence
Quantification of GPR171-fluorescence was performed using ImageJ (NIH) on automatically
thresholded images as previously described [137, 138]. Up to 5 images of the vlPAG representative
of both left and right hemispheres and across different rostro-caudal positions were analyzed per
animal per group. They were analyzed as independent measurements to account for the structural
and functional heterogeneity of the PAG [58, 59, 60, 61]. Ten cells in the field of view were ran-
domly selected along with three areas representing background fluorescence. The fluorescence from
GPR171 signal was calculated using the formula for Corrected Total Cell Fluorescence (CTCF) (In-
tegrated Density – (area of selection×mean background fluorescence)). The measurements have
been presented in arbitrary units (AU).
4.2.9 Quantitative RT-PCR
Immediately following the final behavioral testing, a subset of the subjects (3-5/group) were
euthanized by decapitation and the periaqueductal gray was dissected and snap-frozen on dry ice.
The tissue samples were stored at -80°C until further processing. RNA was extracted from the tis-
sues using Trizol (Cat. 15596026, Invitrogen) and RNeasy Plus Mini Kit (Cat. 74136, Qiagen)
following the manufacturer’s instructions. The eluted RNA was quantified using a Qubit 4 fluo-
rometer (Invitrogen). cDNA was prepared using the Maxima first-strand synthesis kit for qRT-PCT
(Cat. K1642, Thermo-Fisher) following the manufacturer’s instructions. Samples were prepared
using SYBR green (iTaq Universal SYBR Green Supermix, Cat. 1725121, Bio-Rad, CA) for gene
expression analysis on a real-time thermocycler (CFX384 Touch, Bio-Rad). Custom primers as
described previously [38] were used for GAPDH, GPR171, and ProSAAS (Integrated DNA Tech-
nologies). The synthesized cDNA was assayed in triplicate and analyzed using the 2∆∆Ct method.
Here, Ct indicates the cycle number at which the fluorescence signal crosses an arbitrary threshold
within the exponential phase of the amplification curve. To calculate ∆∆Ct, we used the formula
∆∆Ct = {(Cttarget:treated sample – CtGAPDH:treated sample) – (Cttarget:control sample – CtGAPDH:control sample)}.
The value of the control sample was set to 100% and all samples were evaluated with respect to the
control. Negative control reactions were performed to ascertain contaminant-free cDNA synthesis
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and primer specificity was evaluated using melt curve analyses. The primer sequence information
can be found in the supplementary material (Table S1).
4.2.10 Statistical Analysis
Results are presented as mean ± standard error of mean (SEM). Statistical analyses of behav-
ioral studies were performed using a repeated measures two-way analysis of variance (ANOVA)
combined with Bonferroni’s post-hoc test. Normality of data was evaluated using the D-Agostino
and Pearson test. Statistical analyses of qRT-PCR data and fluorescence quantification were per-
formed using a one-way ANOVA combined with a Tukey’s post-hoc test. Experimenters were
blinded to drug treatment (saline and MS15203), but not to the pain state during behavioral stud-
ies and statistical analysis. All graphing and statistical analyses were performed using Prism 9.0
(GraphPad, San Diego, CA).
4.3 Results
4.3.1 GPR171 agonist does not reduce chronic inflammatory pain in female mice
We used a model of CFA-induced inflammatory pain to study the effect of GPR171 agonism
on pain relief (Fig. 4.1A). In females, (n=6-8/group), intra-plantar CFA injection produced inflam-
matory pain and associated thermal hypersensitivity as measured by a plantar test. The estrus stage
did not impact the subjects’ thermal thresholds (Fig. 4.5A). A repeated measures two-way ANOVA
indicated significant differences in thermal thresholds over the course of the study (Time [F (3.159,
88.44) = 36.78, p<0.0001]; Treatment [F (3, 28) = 14.57, p¡0.0001]; Time x Treatment [F (12, 112)
= 8.211, p¡0.0001]). A Bonferroni’s post-hoc test revealed that the female mice developed thermal
hypersensitivity 24 hours following the CFA insult (Fig. 4.1B: Day 1, Control + Saline vs CFA +
Saline or CFA + MS15203, p¡0.001) which persisted through the duration of the study (Fig. 4.1B:
Day 5 post-drug, Control + Saline vs CFA + Saline, p<0.0001). However, the Bonferroni’s post-hoc
analysis revealed that despite chronic (once-daily) treatment with MS15203, there was no change
in the thermal latency of female mice with inflammation-induced hypersensitivity (Fig. 4.1B: Day
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Fig. 4.1: GPR171 agonist does not reduce chronic inflammatory pain in female mice. (A) An
illustrative timeline describing the experimental design of CFA-induced inflammatory pain followed
by MS15203 treatment. (B) Female mice (n=6-8/group) injected with CFA in their hind paws
developed rapid thermal hypersensitivity as measured by a plantar test. Chronic treatment with
MS15203 failed to reduce inflammatory pain as noted by the persistence of thermal hypersensitivity
through Day 5. Repeated measured two-way ANOVA with Bonferroni’s post-hoc test. (C) Analysis
of gene expression changes within the periaqueductal gray (PAG) reveals that the transcript levels
of GPR171 and its endogenous ligand, PCSK1N, are unchanged in female mice (n=4-5/group)
irrespective of inflammatory pain status or MS15203 treatment. One-way ANOVA with Tukey’s
post-hoc test.
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5 post-drug, CFA + Saline vs CFA + MS15203, p>0.05). MS15203 treatment alone did not alter
the thermal latencies of females in the Control group.
We then performed qRT-PCR on dissected whole periaqueductal gray (PAG) tissue from a sub-
set of females (n=4-5/group) to evaluate gene expression changes in GPR171 or its endogenous
ligand, PCSK1N (Fig. 4.1C). The PAG is a critical modulator of antinociception within the de-
scending pain pathway and is a site of action of endogenous opioid activity [50, 59]. A one-way
ANOVA indicated no significant differences between treatment groups on evaluation of GPR171
(Treatment F (3, 13) = 0.71, p>0.05) or PCSK1N (Treatment F (3, 13) = 1.68, p>0.05) expression
in the PAG.
4.3.2 GPR171 agonist reduces chronic inflammatory pain in male mice
We performed a similar experimental paradigm as Fig. 4.1A to evaluate the analgesic prop-
erties of GPR171 in male mice. In males, (n=5-6/group), intra-plantar CFA injection produced
inflammatory pain and thermal hypersensitivity on the plantar test. A repeated measures two-way
ANOVA indicated significant differences in thermal thresholds over the course of the study (Time
[F (3.025, 57.48) = 19.48, p¡0.0001]; Treatment [F (3, 19) = 27.08, p<0.0001]; Time × Treatment
[F (12, 76) = 7.417, p<0.0001]). Similar to the females, the male mice injected with CFA developed
thermal hypersensitivity 24 hours later as revealed by a Bonferroni’s post-hoc test (Fig. 4.2A: Day
1, Control + Saline vs CFA + Saline or CFA + MS15203, p<0.0001). The Bonferroni’s post-hoc
analysis also revealed that acute MS15203 did not improve thermal latencies in CFA-treated male
mice (Fig. 4.2A: Day 1 post-drug, Control + Saline vs CFA + MS15203, p<0.01). However, 3 days
of once-daily MS15203 treatment increased thermal latencies of male mice and this improvement
was sustained through the 5-day chronic treatment paradigm (Fig. 4.2A: Day 3 post-drug, CFA
+ Saline vs CFA + MS15203, p<0.05 and Day 5 post-drug, CFA + Saline vs CFA + MS15203,
p<0.001).
We performed immunofluorescence staining and quantification of GPR171 in the PAG of male
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Fig. 4.2: GPR171 agonist reduces chronic inflammatory pain in male mice. (A) Male mice (n=5-
6/group) injected with CFA in their hind paws developed rapid thermal hypersensitivity as measured
by a plantar test. Chronic treatment with MS15203 alleviated inflammatory pain by Day 3 of the
treatment and the analgesia was ongoing through Day 5 as measured by an increase in thermal
latencies on the plantar test. Repeated measured two-way ANOVA with Bonferroni’s post-hoc test.
(B) Fluorescence immunostaining and (C) quantification of GPR171 signal show that the protein
levels of GPR171 are unchanged in the ventrolateral PAG (vlPAG) of male mice (n=10-12 images
each from 2 mice/group). (D) Analysis of gene expression changes within the PAG reveals that
the transcript levels of GPR171 and its endogenous ligand, PCSK1N, are unchanged in male mice
(n=4-5/group). One-way ANOVA with Tukey’s post-hoc test. ****p<0.0001. Scale bar = 50 µm.
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mice to visualize receptor localization and evaluate GPR171 protein levels within the ventrolateral
PAG (vlPAG) (Fig. 4.2: C, D). A one-way ANOVA of fluorescence intensities indicated no signifi-
cant differences between treatment groups on quantification of GPR171 protein levels in the vlPAG
(Treatment F (3, 36) = 1.97, p>0.05).
We then performed qRT-PCR on dissected whole PAG from males to evaluate gene expression
changes in GPR171 and PCSK1N (Fig. 4.2B). A one-way ANOVA indicated no significant differ-
ences between treatment groups on evaluation of GPR171 (Treatment F (3, 16) = 2.06, p>0.05) or
PCSK1N (Treatment F (3, 16) = 3.07, p>0.05) expression in the PAG.
4.3.3 GPR171 agonist does not alleviate chronic neuropathic pain in female mice
We employed a model of chemotherapy-induced peripheral neuropathy (CIPN) to study the ef-
fects of GPR171 agonist treatment on chronic pain (Fig. 4.3A). In females (n=6-7/group), paclitaxel
produced allodynia as assessed by an electronic von Frey sensor. The estrus stage did not impact
the subjects’ mechanical thresholds (Fig. 4.5B). A repeated measures two-way ANOVA indicated
significant differences in mechanical thresholds over the course of the study (Time [F (3.77, 98)
= 63.87, p<0.0001]; Treatment [F (3, 26) = 44.36, p<0.0001]; Time x Treatment [F (15, 130) =
12.54, p<0.0001]). A Bonferroni’s post-hoc test revealed that the female mice developed allodynia
by Day 5 following the first dose of paclitaxel (Fig. 4.3B: Day-5, Vehicle + Saline vs Paclitaxel +
Saline or Paclitaxel + MS15203, p<0.001). Allodynia was maintained through the duration of the
study and was ongoing on Day 15 prior to the initiation of pharmacological intervention (Fig. 4.3B,
Day - 15, Vehicle + Saline vs. Paclitaxel + Saline or Paclitaxel + MS15203, p<0.0001). We then
tested the effect of MS15203 at both acute (30min) and chronic (5 days) dosing paradigms. A Bon-
ferroni’s post-hoc analysis revealed that neither acute nor chronic MS15203 treatment increased the
mechanical thresholds of Paclitaxel + MS15203-treated females (Fig. 4.3B: Day 15 post-test and
Day 20, Vehicle + Saline vs Paclitaxel + MS15203, p<0.0001). The compound MS15203 alone did
not have any effect in vehicle-treated female mice.
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Fig. 4.3: GPR171 agonist does not reduce chronic neuropathic pain in female mice. (A) An illus-
trative timeline describing the experimental design of chemotherapy-induced peripheral neuropathy
followed by MS15203 treatment. (B) Female mice (n=6-7/group) treated with paclitaxel (16 mg/kg
cumulative, i.p.) developed allodynia by Day 5 of the study as measured by the von Frey test.
Chronic treatment with MS15203 from Day 15 through Day 20 failed to reduce allodynia as noted
by the persistence of mechanical hypersensitivity through Day 20. Repeated measures two-way
ANOVA with Bonferroni’s post-hoc test. (C) Analysis of gene expression changes within the pe-
riaqueductal gray (PAG) reveals that the transcript levels of GPR171 and its endogenous ligand,
PCSK1N, are unchanged in female mice (n=4-5/group) irrespective of neuropathic pain status or
MS15203 treatment. One-way ANOVA with Tukey’s post-hoc test.
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We proceeded to perform qRT-PCR on dissected PAG from female mice (4-5/group) to as-
sess whether gene expression levels of GPR171 and its endogenous ligand PCSK1N are altered
following neuropathic pain and MS15203 treatment. A one-way ANOVA revealed that the expres-
sion levels of GPR171 are unchanged in the PAG of female mice irrespective of pain condition or
MS15203 treatment (F (3,13) = 0.572, p>0.05). Similarly, the expression levels of PCSK1N were
also unchanged in the PAG of female mice across pain conditions or MS15203 treatment (F (3,13)
= 0.076, p>0.05).
4.3.4 GPR171 agonist reduces chronic neuropathic pain in male mice
We performed a similar experimental paradigm as Fig. 4.3A using male mice to assess the anti-
allodynic effect of MS15203. In males (n=6-7/group), paclitaxel produced allodynia as assessed by
manual von Frey filaments using the up-down method. A repeated measures two-way ANOVA in-
dicated significant differences in mechanical thresholds over the course of the study (Time [F (3.31,
92.71) = 38, p<0.0001]; Treatment [F (3, 28) = 82.53, p<0.0001]; Time x Treatment [F (15, 140)
= 13.36, p<0.0001]). A Bonferroni’s post-hoc test revealed that the male mice developed allodynia
by Day 5 following the first dose of paclitaxel (Fig. 4.4A: Day-5, Vehicle + Saline vs Paclitaxel
+ Saline or Paclitaxel + MS15203, p<0.001). Allodynia was maintained through the duration of
the study and was ongoing on Day 15 prior to the initiation of pharmacological intervention (Fig.
4.4A, Day - 15, Vehicle + Saline vs Paclitaxel + Saline or Paclitaxel + MS15203, p<0.0001). We
then tested the effect of MS15203 at both acute (30min) and chronic (5 days) dosing paradigms. A
Bonferroni’s post-hoc analysis revealed that acute MS15203 treatment did not alter the mechani-
cal thresholds of male mice in neuropathic pain (Fig. 4.4A: Paclitaxel + MS15203 vs Paclitaxel +
Saline, Day 15 baseline vs post-test, Bonferroni p>0.05). However, following 5 days of repeated
dosing, MS15203 treatment increased the mechanical thresholds of mice in neuropathic pain com-
pared to their saline-treated counterparts (Fig. 4.4A: Paclitaxel + MS15203 vs Paclitaxel + Saline,
Day 20, Bonferroni p<0.05). The compound MS15203 alone did not have any effect in vehicle-
treated male mice.
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Fig. 4.4: GPR171 agonist reduces chronic neuropathic pain in male mice. (A) Male mice (n=6-
7/group) treated with paclitaxel (16 mg/kg cumulative, i.p.) developed allodynia by Day 5 of the
study as measured by the von Frey test. Chronic, but not acute, treatment with MS15203 reduced
the duration of allodynia as noted by the significant increase in mechanical thresholds compared to
Paclitaxel + Saline treated mice. Repeated measures two-way ANOVA with Bonferroni’s post-hoc
test. (B) Fluorescence immunostaining and (C) quantification of GPR171 signal show that protein
levels of GPR171 are decreased following neuropathic pain and chronic treatment with MS15203
results in an increase of GPR171 in the vlPAG (10-12 images each from 2 mice/group). (D) Anal-
ysis of gene expression changes within the PAG reveals that the transcript levels of GPR171 and
its endogenous ligand, PCSK1N, are unchanged in male mice (n=4-5/group) irrespective of neuro-
pathic pain status or MS15203 treatment. One-way ANOVA with Tukey’s post-hoc test. *p<0.05,
**p<0.01, ****p<0.0001. Scale bar = 50 µm.
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We performed immunostaining for the receptor GPR171 and quantified fluorescence intensity
within the ventrolateral PAG (vlPAG) (Fig. 4.4B,C). Intriguingly, a one-way ANOVA of the fluores-
cence intensities revealed significant differences between the groups (F (3,35) = 10.15, p<0.0001).
A Tukey’s post-hoc test revealed that neuropathic pain resulted in a significant decrease of GPR171
immunostaining compared to vehicle-treated controls (Fig. 4.4D: Vehicle + Saline vs Paclitaxel +
Saline, Tukey’s p<0.05). Further, the post-hoc analysis revealed that following chronic MS15203
treatment, there was a rescue effect and, in fact, the levels of GPR171 were elevated compared to
the vehicle-treated controls (Fig. 4.4D: Vehicle + Saline vs Paclitaxel + MS15203, Tukey’s p<0.05).
We proceeded to perform qRT-PCR on dissected PAG from male mice to assess whether gene
expression levels of GPR171 and PCSK1N are altered following neuropathic pain and MS15203
4.4D). A one-way ANOVA revealed that the expression levels of GPR171 are unchanged in the
PAG of male mice irrespective of pain condition or MS15203 treatment (F (3,13) = 0.572, p>0.05).
Similarly, the expression levels of PCSK1N were also unchanged in the PAG of male mice across
pain conditions or MS15203 treatment (F (3,13) = 0.076, p>0.05).
4.4 Discussion
The current study establishes that the receptor GPR171 is a promising target for the treatment
of chronic pain in males. A synthetic agonist for the receptor, MS15203, decreases the duration
of both allodynia caused by neuropathic pain and thermal hypersensitivity caused by inflammatory
pain in male mice. Interestingly, MS15203 does not reduce allodynia nor thermal pain in female
mice using the same dose administered in males. Further, although GPR171 receptor immunostain-
ing is unaltered in males after chronic inflammation, neuropathic pain induces a decrease in GPR171
protein levels which is rescued following chronic MS15203 treatment. The gene expression levels
of GPR171 and its endogenous ligand, PCSK1, are unaltered in the PAG. Further, while GPR171
activation is recognized to promote food intake [37], we note that our 5-day treatment did not result
in significant alterations in the subjects’ weights (Fig. 4.6A-D).
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The development of CFA-induced inflammatory pain occurs over a biphasic response time.
The initial course of inflammation occurs over the first 24 hours, followed by persistent pain lasting
over the course of a week. We report here that systemic administration of the compound MS15203
decreases the duration of CFA-induced inflammatory pain, in a sex-dependent manner, after 3 days
of treatment following the initial inflammatory phase. We also note that while this reduction of
chronic pain is sustained over the course of the study in male mice, female mice do not display
any reduction of thermal hypersensitivity over the course of the study. In previous studies assessing
therapeutic options for chemotherapy-induced neuropathic pain, we noted that mechanical allody-
nia is most pronounced by Day 15 of the study and persists through 30 days [33]. We assessed
allodynia following 5 days of once-daily MS15203 treatment (10 mg/kg i.p.). We report here that
systemic administration of the compound MS15203 decreases the duration of paclitaxel-induced
peripheral neuropathy and associated allodynia after 5 days of treatment in male mice. While the
pathophysiology of sex differences in neuropathic pain induced by chemotherapy is unclear, it is in-
deed a remarkable observation that the GPR171 activation did not promote alleviation of allodynia
in females in chronic neuropathic pain.
The absence of changes in ProSAAS or GPR171 mRNA indicate that a 5-day, once-daily
treatment regimen does not alter receptor or ligand gene expression in the brain although the drug
does exert a physiological effect at this timescale. A recent study showed that peripheral sensory
neurons contribute to the pain relief seen with GPR171 activation [139]. While this observation
explains alterations at the peripheral level in addition to spinal sensitization to chronic pain, the role
of alterations in PAG connectivity and excitability is well established in the context of chronic pain
paradigms [140, 141, 142]. The absence of gene expression changes of GPR171 or PCSK1N within
the PAG, while observing a modulation of protein levels is indeed a remarkable observation. We
postulate that the transcript levels obtained from whole dissected PAG are not representative of the
protein levels within the local vlPAG region, a highly variable relationship that has been reviewed
previously [143]. The decrease in GPR171 protein levels in the vlPAG following neuropathic pain
is comparable to reports of decreased mu opioid receptor availability following chronic pain [144].
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We previously found synergistic antinociceptive effects of MS15203 with morphine, indicating the
receptors could also be similar in their physiological modulation.
GPR171 is an inhibitory Gαi/o coupled receptor which inhibits cAMP production [37]. Based
on our study showing GPR171 in GABA neurons in the PAG, we hypothesize that activation of
GPR171 leads to a decrease in GABA release [40]. This in turn leads to antinociception by exci-
tation of output neurons in the medulla. In addition, GPR171 is found in the dorsal root ganglion
and alleviates inflammatory pain following intrathecal administration of a GPR171 agonist, pre-
sumably by inhibiting TRP ion channels [139]. Since we administered the agonist systemically, it
is likely that it is working within the central and peripheral nervous system to alleviate pain. In
addition, the increase in the endogenous ligand ProSAAS, seen in circulating CSF of fibromyalgia
patients, is likely a consequence of adaptations towards restoring GPR171 signaling as we have
observed a decrease in brain-specific GPR171 receptor expression in males with neuropathic pain
[129]. The lack of alleviation of neuropathic or inflammatory pain in females following chronic
MS15203 treatment warrants further investigation. Previous studies have indicated that C57BL/6
mice display stable pain behaviors across estrus stages [145, 146]. It is plausible that the dose of
agonist administered (10mg/kg, i.p.) was insufficient to produce a physiological response in fe-
males. Further, there is considerable evidence of heightened immune activation in females at both
central and peripheral sensory processing regions, which contribute to mechanical and thermal hy-
persensitivity [91, 147, 148, 149]. The heightened microglial activation in the PAG in females has
been shown to reduce morphine-induced antinociception [150]. While there is a paucity of studies
examining immune interactions with GPR171 activity, the possibility of the immune microenviron-
ment modulating GPR171-dependent analgesic activity cannot be ruled out. Further, studies with
female mice have reported that the sex-specific differences in chronic pain are driven in part by the
action of hormones and are peripherally regulated by TRP channels [145, 151]. As GPR171 exerts
its peripheral effects via TRP channels on sensory afferents in male mice, the microenvironment in
this region can be postulated to contribute to the observed sex differences [139]. Further, as the gene
encoding GPR171 is located on chromosome 3 of the mouse, the observed differences in behavior
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cannot be attributed to sex chromosome-linked causes. Indeed, sex differences in antinociception
have been found in other systems such as the fatty acid-derived resolvin D5, that was able to pro-
duce antinociception in males with neuropathic or inflammatory pain, but not in females [152]. Our
findings thus identify GPR171 not only as a novel target for the treatment of chronic inflammatory
and neuropathic pain, but also one that displays sexual dimorphism in pain regulation.
Chronic inflammatory and neuropathic pain present public health concerns without efficacious
treatment options. Our findings suggest that the receptor GPR171 is a therapeutic target for the treat-
ment of multiple modalities of chronic pain in a sex-dependent manner and its agonist, MS15203,
can be used to treat chronic pain.
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Supplementary Material
Fig. 4.5: Estrus stage does not impact baseline thresholds of female mice. Female mice do not show
significant differences in their A) thermal thresholds or B) mechanical thresholds on Day 0 of the
chronic pain studies. Two-way repeated measures ANOVA indicated significant differences in the
thresholds of the mice in inflammatory or neuropathic pain. However, a Bonferroni’s post-hoc test
revealed that there were no differences in the baseline thresholds of mice in their respective studies.




Table 4.1: Primer sequences for quantitative RT-PCR.
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Fig. 4.6: MS15203 treatment does not produce significant weight gain in male or female mice.
Once-daily injection of MS15203 (10mg/kg, i.p.) for 5 days does not produce significant weight
grain in male (A, C) or female (B, D) mice. A two-way repeated measures ANOVA indicated sig-
nificant differences in weight changes in mice in the chemotherapy-induced peripheral neuropathy
(CIPN) study. However, a Bonferroni’s post-hoc test revealed that there were no significant differ-





This thesis lays the groundwork in clarifying how chronic opioid treatment is manifested at the
intracellular signaling level. Through multiple levels of analysis including molecular, cellular, and
behavioral studies, this thesis provides substantial evidence of elevated levels of intracellular protein
kinases following morphine tolerance. In a step further, this thesis has also included female cohorts
where possible, a group that has been underrepresented in studies of opioid neuropharmacology.
Alongside the advances made in our basic understanding of the neurobiology of opioid tolerance,
this thesis also explores the therapeutic potential of a novel G-protein Coupled Receptor (GPCR) in
the treatment of chronic pain. Pre-clinical translational studies such as the one in this thesis provide
a foundation on which therapeutic leads are evaluated for drug development.
The opioid crisis in the United States traces its history to the 1980s, much before deadly mortal-
ity rates that brought this issue to the forefront in the 2010s. The subject of multiple documentaries
and lawsuits, the opioid crisis has largely been borne from the over-marketing and over-prescription
of synthetic opioids for non-critical pain patients [153]. In addition to the downplayed risks of de-
pendence to these opioids, the prescribing physicians and pharmacies were largely remiss in a plan
to taper usage, leading to rampant misuse.
As opioids were primarily prescribed for the management of pain in patients, the scientific
community sought to decouple the analgesic property of opioids from their negative side effects. To
achieve this decoupling, it was postulated that following activation of the µ-opioid receptor by its ag-
onist, the G-protein-dependent pathway contributed to analgesia whereas the β-Arrestin-dependent
pathway contributed to the negative effects such as respiratory depression – the most common cause
of overdose deaths [53]. While this theory did not ultimately hold water, it opened an intriguing di-
mension in the study of the intracellular signaling in opioid neuropharmacology [154]. The intracel-
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lular signatures of signaling pathway dynamics in the brain following µ-opioid receptor activation
have been largely understudied although they contribute to the physiological effects of the opioid
drug. This thesis has made large strides in understanding these complex cellular processes in vivo.
In the realm of neurobiology of opioid analgesia, the ventrolateral periaqueductal gray (vlPAG)
is particularly important for the continued analgesic effect of the drug. While this brain region is not
actively involved in opioid-induced reward, it is a critical regulator of opioid antinociceptive toler-
ance – a phenomenon wherein repeated and persistent use of an opioid results in a decreased ability
of the particular dose to provide desired pain relief. Repeated microinjections of opioids into the
vlPAG, but not other reward-related areas produces antinociceptive tolerance [41]. However, not all
opioids are created equally, with some opioids preferentially activating G-protein signaling while
others are biased towards the β-Arrestin pathway [155]. This dimorphism adds another layer of
complexity to our understanding of opioid receptor signaling, such that while ultimately the behav-
ioral output is antinociception, the intracellular signaling, and probably the mechanism of tolerance
are varied depending upon the opioid studied.
Morphine, a prototypical opioid narcotic and a partial agonist of the µ-opioid receptor, acts on
the µ-opioid receptors in the vlPAG to produce antinociception. Chronic treatment with morphine
produces antinociceptive tolerance on acute thermal pain tests. Early investigation into the role of
the vlPAG in regulating this behavior effect showed that morphine tolerance is associated with el-
evated levels of β-Arrestin-dependent ERK signaling in this brain region. Further, cellular studies
showed elevated levels of the G-protein downstream kinases, Protein Kinase-A (PKA) and Protein
Kinase-C (PKC). However, the activation patterns of PKC and PKA have not been clarified in native
tissue and have remained poorly understood in females.
In Chapter 2 of this thesis, quantification of immuno-fluorescence is applied to draw conclu-
sions about the levels of protein activation in the vlPAG. This particular brain region is restrictively
small in mice such that dissecting the vlPAG and extracting total protein from the tissue would not
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yield assayable sample without pooling across multiple animals. In order to better compare inter-
individual differences and gain and understanding of intracellular signaling dynamics specifically
within the vlPAG, quantitative immunofluorescence was selected as the most appropriate methodol-
ogy. In doing so, the activation levels of the kinases ERK 1/2, PKC, and PKA were found to be the
highest in chronic morphine-treated male and female mice, as compared to mice that were treated
with saline or acute morphine. In addition, following acute morphine treatment, only the levels of
ERK 1/2 were significantly elevated in the vlPAG. This study also showed that activated ERK 1/2
was present within the endosomes of only the chronic morphine-treated mice, indicating a role for
β-Arrestin in internalizing the MOPr after long-term opioid treatment. Intriguingly, this study added
substantial evidence to the postulate that following chronic morphine treatment, there is a shift in
ERK 1/2 activation from a G-protein-dependent pathway to a β-Arrestin-dependent pathway, thus
acting as an indicator of intracellular adaptations that occur in the vlPAG [14, 67].
As Chapter 2 of this thesis provides the basic framework for clarifying alterations in kinase
signaling following morphine tolerance, Chapter 3 of the thesis focuses on a specific kinase, PKC,
which is elevated following chronic morphine treatment. This kinase is recruited to the receptor to
drive desensitization after morphine-induced activation of the MOPr. Interfering with PKC signal-
ing would potentially drive other redundancies to phosphorylate the receptor and initiate the receptor
recycling process. Chapter 3 of this thesis describes efforts to target PKC activity and observe be-
havioral modulation of morphine antinociceptive tolerance.
In Chapter 3 of the thesis, the specific contribution of PKC activity in the vlPAG towards
the development of antinociceptive tolerance to morphine was examined in great detail. Targeted
delivery of the PKC inhibitor Gö-7874 into the vlPAG was achieved through stereotaxic cannula
implantation and repeated drug delivery. While one dose (2nM) of PKC inhibitor did not have an
effect of morphine activity, repeated administration of the inhibitor (16nM cumulative) within the
vlPAG was able to prevent the development of antinociceptive tolerance to repeated systemic ad-
ministration of morphine. Further, in this section, the critical nature of the vlPAG was explicitly
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demonstrated as non-targeted inhibition of PKC did not affect the degree of tolerance to morphine.
This work is significant as it contributes to our understanding of kinase-dependent modulation
of MOPr activity within the vlPAG. Based on this work, it can be postulated that the inhibition of
PKC drives a different kinase to terminate G-protein signaling and effectively recycle the receptor
to sustain morphine antinociceptive activity. This has far-reaching clinical implications. By pro-
longing the window in which morphine produces pain relief, it obviates the necessity to increase the
dose of morphine in opioid-tolerant patients. To pursue this avenue further, it would be of interest
to test the behavioral consequences of PKC inhibition following the development of opioid toler-
ance. This would provide the community with more information about the critical role of PKC in
the temporal regulation of MOPr recycling.
Given the broad range of negative side effects associated opioid use, it is indeed a worthwhile
endeavor to seek alternative pharmacological interventions to address chronic pain. The primary
motivation behind Chapter 4 of this thesis is the proof-of-concept validation that the non-opioid
GPCR, GPR171, is a therapeutic target for chronic pain. The identification of GPR171 as an in-
hibitory GPCR that enhances the antinociceptive effects of morphine in acute pain tests, in addition
to being present in the same vlPAG neurons as the MOPr, was a pharmacological similarity to the
MOPr that drove the curiosity behind this study. It was a noteworthy observation that sexual di-
morphism emerged when assessing the anti-hyperalgesic and anti-allodynic effects of the GPR171
agonist, MS15203. Given the existence of very few such novel pain therapeutics that display sex
differences in vivo, the mechanistic underpinnings of this effect is deserving of further investigation.
This observation also highlights the drawbacks of therapeutics development without consideration
of sex as a biological variable.
In this thesis, the mouse ventrolateral periaqueductal gray has been shown to exhibit heightened
intracellular protein kinase activation after morphine tolerance. Several of these alterations have
been demonstrated in females for first time, including differential localization of kinases and their
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substrates after morphine tolerance. Manipulation of PKC activity specifically within the vlPAG
has been shown for the first time in vivo to modulate morphine tolerance. These results advance our
understanding of intracellular processes that are altered in a critical pain processing center of the
brain as a result of chronic morphine treatment. Further, this thesis describes an in vivo application
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